Cabazitaxel – Uses, Dosage, Side Effects, Interaction

Last updated: February 8, 2026Reviewed date: February 8, 2026Reading time: 71 min read
Patient Tools

Read, save, and share this guide

Use these quick tools to make this medical article easier to read, print, save, or share with a family member.

Patient Mode

Understand this article easily

Switch between simple English and easy Bangla patient notes. This is for education and does not replace a doctor consultation.

Cabazitaxel is a taxane and antineoplastic agent which is currently used in the therapy of castration-resistant metastatic prostate cancer after the failure of docetaxel. Therapy with cabazitaxel has been associated with a low rate of serum enzyme elevations but has not been linked to cases of...

For severe symptoms, danger signs, pregnancy, child illness, or sudden worsening, seek urgent medical care.

বাংলা রোগী নোট এখনো যোগ করা হয়নি। পোস্ট এডিটরে “RX Bangla Patient Mode” বক্স থেকে সহজ বাংলা সারাংশ যোগ করুন।

এই তথ্য শিক্ষা ও সচেতনতার জন্য। এটি ডাক্তারি পরীক্ষা, রোগ নির্ণয় বা প্রেসক্রিপশনের বিকল্প নয়।

Article Summary

Cabazitaxel is a taxane and antineoplastic agent which is currently used in the therapy of castration-resistant metastatic prostate cancer after the failure of docetaxel. Therapy with cabazitaxel has been associated with a low rate of serum enzyme elevations but has not been linked to cases of clinically apparent acute liver injury, although it can cause severe hypersensitivity infusion reactions which in some instances can be associated...

Key Takeaways

  • This article explains Mechanism of Action in simple medical language.
  • This article explains Indication in simple medical language.
  • This article explains Contraindication in simple medical language.
  • This article explains Dosage in simple medical language.
Educational health guideWritten for patient understanding and clinical awareness.
Reviewed content workflowUse writer and reviewer profiles for stronger trust.
Emergency safety firstUrgent warning signs are highlighted below.

Seek urgent medical care if you notice

These warning signs are general safety guidance. Local emergency numbers and clinical judgment should always come first.

  • Severe symptoms, breathing difficulty, fainting, confusion, or rapidly worsening illness.
  • New weakness, severe pain, high fever, or symptoms after a serious injury.
  • Any symptom that feels urgent, unusual, or unsafe for the patient.
1

Emergency now

Use emergency care for severe, sudden, rapidly worsening, or life-threatening symptoms.

2

See a doctor

Book a professional medical evaluation if symptoms persist, worsen, recur often, affect daily activities, or occur in a high-risk patient.

3

Learn safely

Use this article to understand possible causes, tests, treatment options, prevention, and questions to ask your clinician.

Before reading

RX Patient Tools

Use these quick guides before reading the article, or return to them when you need help preparing questions for a doctor.

Start here Choose the right pathway for symptoms, reports, medicines, or urgent warning signs. Disease article roadmap Read this topic step by step: meaning, symptoms, warning signs, diagnosis, treatment, prevention, and follow-up. Treatment planner Prepare questions about treatment choices, benefits, risks, side effects, and follow-up. Family & caregiver guide Organize symptoms, reports, medicines, questions, and follow-up safely. Nutrition & diet guide Prepare food, hydration, supplement, and medicine-timing questions safely. Prevention guide Organize risk factors, protective habits, screening, and warning signs. Recovery guide Prepare a safe plan for activity, rehabilitation, warning signs, and follow-up.

Cabazitaxel is a taxane and antineoplastic agent which is currently used in the therapy of castration-resistant metastatic prostate cancer after the failure of docetaxel. Therapy with cabazitaxel has been associated with a low rate of serum enzyme elevations but has not been linked to cases of clinically apparent acute liver injury, although it can cause severe hypersensitivity infusion reactions which in some instances can be associated with acute liver injury. Cabazitaxel is prepared by semi-synthesis with a precursor extracted from yew needles (10-deacetylbaccatin III). It was approved by the U.S. Food and Drug Administration (FDA) on June 17, 2010.

Cabazitaxel is a semi-synthetic derivative of the natural taxoid 10-deacetylbaccatin III with potential antineoplastic activity. Cabazitaxel binds to and stabilizes tubulin, resulting in the inhibition of microtubule depolymerization and cell division, cell cycle arrest in the G2/M phase, and the inhibition of tumor cell proliferation. Unlike other taxane compounds, this agent is a poor substrate for the membrane-associated, multidrug resistance (MDR), and P-glycoprotein (P-gp) efflux pump and may be useful for treating multidrug-resistant tumors. In addition, cabazitaxel penetrates the blood-brain barrier (BBB).

Cabazitaxel is a tetracyclic diterpenoid that is 10-deacetylbaccatin III having O-methyl groups attached at positions 7 and 10 as well as an O-(2R,3S)-3-[(tert-methoxycarbonyl)amino]-2-hydroxy-3-phenylpropanoid group attached at position 13. Acts as a microtubule inhibitor, binds tubulin and promotes microtubule assembly, and simultaneously inhibits disassembly. It has a role as an antineoplastic agent and a microtubule-stabilizing agent. It is functionally related to a 10-deacetylbaccatin III.

Mechanism of Action

Cabazitaxel is a microtubule inhibitor. Cabazitaxel binds to tubulin and promotes its assembly into microtubules while simultaneously inhibiting disassembly. This leads to the stabilization of microtubules, which results in the interference of mitotic and interphase cellular functions. The cell is then unable to progress further into the cell cycle, being stalled at metaphase, thus triggering apoptosis of the cancer cell.

Indication

  • For treatment of patients with hormone-refractory metastatic prostate cancer previously treated with a docetaxel-containing treatment regimen. Cabazitaxel is a taxane and antineoplastic agent which is currently used in the therapy of castration-resistant metastatic prostate cancer after the failure of docetaxel.
  • Jevtana in combination with prednisone or prednisolone is indicated for the treatment of patients with hormone-refractory metastatic prostate cancer previously treated with a docetaxel-containing regimen.
  • Treatment of prostate cancer
  • Treatment of patients with hormone-refractory metastatic prostate cancer previously treated with a docetaxel-containing regimen.
  • Prostate cancer that has metastasized (spread to other parts of the body) in men whose cancer is castrate-resistant (has not responded to treatments that lower testosterone levels) and who have already been treated with chemotherapy that included docetaxel.
  • Refractory, metastatic hormone-refractory Prostate cancer

Use in Cancer

Cabazitaxel is approved to be used with prednisone to treat:

  • Prostate cancer that has metastasized (spread to other parts of the body) in men whose cancer is castrate-resistant (has not responded to treatments that lower testosterone levels) and who have already been treated with chemotherapy that included docetaxel.

Cabazitaxel is also being studied in the treatment of other types of cancer.

Contraindication

  • bacterial infection. সহজ বাংলা: ব্যাকটেরিয়ার বিরুদ্ধে লড়াই করা শ্বেত রক্তকণিকা।" data-rx-term="neutrophil" data-rx-definition="Neutrophil is a white blood cell important for fighting bacterial infection. সহজ বাংলা: ব্যাকটেরিয়ার বিরুদ্ধে লড়াই করা শ্বেত রক্তকণিকা।">Neutrophil counts of ≤1,500/mm3
  • History of severe hypersensitivity to or polysorbate 80
  • a bad infection
  • caloric undernutrition
  • dehydration
  • anemia
  • decreased blood platelets
  • low levels of a type of white blood cell called neutrophils
  • liver problems
  • severe liver disease
  • acute kidney failure
  • infection, or irritation, often causing pain, swelling, heat, or redness. সহজ বাংলা: শরীরের প্রদাহ; ব্যথা, ফোলা বা লালভাব হতে পারে।" data-rx-term="inflammation" data-rx-definition="Inflammation is the body’s response to injury, infection, or irritation, often causing pain, swelling, heat, or redness. সহজ বাংলা: শরীরের প্রদাহ; ব্যথা, ফোলা বা লালভাব হতে পারে।">inflammation of the bladder with hemorrhage
  • vomiting
  • excessive diarrhea
  • pregnancy
  • lung tissue problem
  • Child-Pugh class A liver impairment
  • Child-Pugh class B liver impairment
  • Child-Pugh class C liver impairment

Dosage

Strengths: 60 mg/1.5 mL

Prostate Cancer

  • 20 mg/m2 IV over one-hour every three weeks
  • Some patients may receive a dose of 25 mg/m2 every three weeks
  • In selected patients, the dose may be increased to 25 mg/m2; primary prophylaxis with G-CSF is recommended in these patients.
  • Use in combination with oral prednisone 10 mg once a day.
  • The dose is based on the calculation of the Body Surface Area (BSA).
  • Give a premedication regimen at least 30 minutes prior to each administration, including antiemetics prophylaxis as needed.
  • Ensure adequate hydration throughout treatment.

Renal Dose Adjustments

  • CrCl 15 mL/min to less than 90 mL/min not requiring hemodialysis: No adjustment necessary
  • End-stage renal dysfunction (CrCl less than 15 mL/min): Use with caution and monitor carefully during treatment.

Liver Dose Adjustments

  • Mild hepatic dysfunction (total jaundice. সহজ বাংলা: জন্ডিসে বাড়তে পারে এমন হলুদ রঞ্জক।" data-rx-term="bilirubin" data-rx-definition="Bilirubin is a yellow pigment that can build up in jaundice. সহজ বাংলা: জন্ডিসে বাড়তে পারে এমন হলুদ রঞ্জক।">bilirubin greater than 1 to 1.5 times upper limit of normal [x ULN] or AST greater than 1.5 x ULN): Maximum dose 20 mg/m2
  • Moderate hepatic dysfunction (total jaundice. সহজ বাংলা: জন্ডিসে বাড়তে পারে এমন হলুদ রঞ্জক।" data-rx-term="bilirubin" data-rx-definition="Bilirubin is a yellow pigment that can build up in jaundice. সহজ বাংলা: জন্ডিসে বাড়তে পারে এমন হলুদ রঞ্জক।">bilirubin greater than 1.5 to 3 x ULN and any AST): Maximum tolerated dose 15 mg/m2; however, the efficacy of this dose is unknown
  • Severe hepatic dysfunction (total jaundice. সহজ বাংলা: জন্ডিসে বাড়তে পারে এমন হলুদ রঞ্জক।" data-rx-term="bilirubin" data-rx-definition="Bilirubin is a yellow pigment that can build up in jaundice. সহজ বাংলা: জন্ডিসে বাড়তে পারে এমন হলুদ রঞ্জক।">bilirubin greater than 3 x ULN): Contraindicated

Dose Adjustments

Dose modifications:

  • Patients at a 20 mg/m2 dose who require dose reduction should decrease their dosage to 15 mg/m2
  • Patients at a 25 mg/m2 dose who require dose reduction should decrease their dosage to 20 mg/m2
  • One additional dose reduction to 15 mg/m2 may be considered

Adjust dosage for the following adverse events:

  • Prolonged (more than 1 week) Grade 3 or higher bacterial infection. সহজ বাংলা: ব্যাকটেরিয়ার বিরুদ্ধে লড়াই করা শ্বেত রক্তকণিকা।" data-rx-term="neutrophil" data-rx-definition="Neutrophil is a white blood cell important for fighting bacterial infection. সহজ বাংলা: ব্যাকটেরিয়ার বিরুদ্ধে লড়াই করা শ্বেত রক্তকণিকা।">neutrophil count, which may increase infection risk. সহজ বাংলা: নিউট্রোফিল কম থাকা, সংক্রমণের ঝুঁকি বাড়তে পারে।" data-rx-term="neutropenia" data-rx-definition="Neutropenia means low neutrophil count, which may increase infection risk. সহজ বাংলা: নিউট্রোফিল কম থাকা, সংক্রমণের ঝুঁকি বাড়তে পারে।">neutropenia despite appropriate medication including G-CSF: Delay treatment until the neutrophil count is greater than 1,500 cells/mm3, then reduce dose by one dose level. Use G-CSF for secondary prophylaxis.
  • Febrile infection. সহজ বাংলা: ব্যাকটেরিয়ার বিরুদ্ধে লড়াই করা শ্বেত রক্তকণিকা।" data-rx-term="neutrophil" data-rx-definition="Neutrophil is a white blood cell important for fighting bacterial infection. সহজ বাংলা: ব্যাকটেরিয়ার বিরুদ্ধে লড়াই করা শ্বেত রক্তকণিকা।">neutrophil count, which may increase infection risk. সহজ বাংলা: নিউট্রোফিল কম থাকা, সংক্রমণের ঝুঁকি বাড়তে পারে।" data-rx-term="neutropenia" data-rx-definition="Neutropenia means low neutrophil count, which may increase infection risk. সহজ বাংলা: নিউট্রোফিল কম থাকা, সংক্রমণের ঝুঁকি বাড়তে পারে।">neutropenia or neutropenic infection: Delay treatment until improvement or resolution, and the neutrophil count is greater than 1,500 cells/mm3, then reduce dose by one dose level.
  • Grade 3 or higher, or persisting diarrhea despite appropriate medication, fluid, and electrolytes replacement: Delay treatment until improvement or resolution, then reduce dose by one dose level.
  • Grade 2 peripheral neuropathy: Delay treatment until improvement or resolution, then reduce dose by one dose level.
  • Grade 3 or higher peripheral neuropathy: Discontinue treatment.

Adjust dosage for use with strong CYP450 3A inhibitors:

  • Avoid the coadministration of strong inhibitors of CYP450 3A drugs.
  • If concomitant use of strong inhibitors of CYP450 3A drugs is inevitable, consider a cabazitaxel 25% dose reduction.

Side Effects

The Most Common

  • heartburn
  • change in ability to taste food
  • loss of appetite
  • weight loss
  • swelling of the inside of the mouth
  • headache
  • joint or back pain
  • numbness, burning, or tingling in the hands, arms, feet, or legs
  • hair loss
  • nausea
  • diarrhea
  • vomiting
  • stomach pain
  • constipation
  • swelling of the face, arms, hands, feet, ankles, or lower legs
  • decreased urination
  • blood in the urine
  • blood in stool
  • changes in stool color
  • dry mouth, dark urine, decreased sweating, dry skin, and other signs of dehydration
  • irregular heartbeat
  • shortness of breath
  • pale skin
  • tiredness or weakness
  • unusual bruising or bleeding

More Common

  • numbness, burning pain, or tingly feeling in your hands or feet;
  • sudden chest pain or discomfort, wheezing, dry cough, feeling short of breath;
  • stomach pain or tenderness, severe vomiting or diarrhea, ongoing constipation;
  • blood in your urine, urinating more often, pain or burning when you urinate;
  • low blood cell counts–fever, chills, muscle pain, mouth sores, skin sores, easy bruising, unusual bleeding, pale skin, cold hands and feet, feeling light-headed or short of breath;
  • signs of stomach bleeding–bloody or tarry stools, coughing up blood or vomit that looks like coffee grounds; or
  • signs of a kidney problem–little or no urinating; painful or difficult urination; swelling in your hands or feet; feeling tired or short of breath.
  • fever, low blood cell counts;
  • numbness or tingling;
  • nausea, vomiting, stomach pain, loss of appetite;
  • constipation, diarrhea;
  • weakness, tired feeling;
  • blood in your urine;
  • back pain, joint pain;
  • cough, shortness of breath;
  • altered sense of taste; or
  • hair loss.

Rare

  • skin redness,
  • chest tightness,
  • lightheadedness,
  • numbness, burning pain, or tingly feeling in your hands or feet,
  • sudden chest pain or discomfort,
  • wheezing,
  • dry cough,
  • shortness of breath,
  • stomach pain or tenderness,
  • severe vomiting,
  • diarrhea,
  • ongoing constipation,
  • blood in your urine,
  • urinating more often,
  • pain or burning when you urinate,
  • fever,
  • chills,
  • muscle pain,
  • mouth sores,
  • skin sores,
  • easy bruising,
  • unusual bleeding,
  • pale skin,
  • cold hands and feet,
  • bloody or tarry stools,
  • coughing up blood,
  • vomiting that looks like coffee grounds,
  • little or no urination,
  • painful or difficult urination,
  • swelling in your hands or feet, and
  • tiredness

Drug Interaction

Pregnancy and Lactation

Pregnancy category D

Pregnancy

JEVTANA can cause fetal harm when administered to a pregnant woman. In non-clinical studies in rats and rabbits, cabazitaxel was embryotoxic, fetotoxic, and abortifacient at exposures significantly lower than those expected at the recommended human dose level. There are no adequate and well-controlled studies in pregnant women using JEVTANA. If this drug is used during pregnancy, or if the patient becomes pregnant while taking this drug, the patient should be apprised of the potential hazard to the fetus. Women of childbearing potential should be advised to avoid becoming pregnant during treatment with JEVTANA [see Use in
Specific Populations

Lactation

Cabazitaxel or cabazitaxel metabolites are excreted in the maternal milk of lactating rats. It is not known whether this drug is excreted in human milk. Within 2 hours of a single intravenous administration of cabazitaxel to lactating rats at a dose of 0.08 mg/kg (approximately 0.02 times the maximum recommended human dose), radioactivity related to cabazitaxel was detected in the stomachs of nursing pups. This was detectable for up to 24 hours post-dose. Approximately 1.5% of the dose delivered to the mother was calculated to be delivered in maternal milk. Because many drugs are excreted in human milk and because of the potential for serious adverse reactions in nursing infants from JEVTANA, a decision should be made on whether to discontinue nursing or discontinue the drug, taking into account the importance of the drug to the mother.

How should this medicine be used?

Cabazitaxel injection comes as a liquid to be given intravenously (into a vein) over 1 hour by a doctor or nurse in a medical facility. It is usually given once every 3 weeks.

You will need to take prednisone every day during your treatment with a cabazitaxel injection. It is important that you take prednisone exactly as prescribed by your doctor. Tell your doctor if you have missed doses or have not taken prednisone as prescribed.

Your doctor may need to stop or delay your treatment or decrease your dose if you experience certain severe side effects. Be sure to tell your doctor how you are feeling during your treatment.

Ask your pharmacist or doctor for a copy of the manufacturer’s information for the patient.

What special precautions should I follow?

Before receiving a cabazitaxel injection,

  • tell your doctor and pharmacist if you are allergic to cabazitaxel injection, any other medications, polysorbate 80, or any of the other ingredients in cabazitaxel injection. Ask your pharmacist for a list of the ingredients.
  • tell your doctor and pharmacist what prescription and nonprescription medications, vitamins, and nutritional supplements you are taking or plan to take. Be sure to mention any of the following: anticoagulants (‘blood thinners) such as warfarin (Coumadin); antifungals such as ketoconazole (Nizoral), itraconazole (Sporanox), and voriconazole (Vfend); antiplatelet medications; aspirin or other nonsteroidal anti-inflammatory drugs (NSAIDs) such as ibuprofen (Advil, Motrin) and naproxen (Aleve, Naprosyn); clarithromycin (Biaxin); certain medications for human immunodeficiency virus (HIV) such as atazanavir (Reyataz), indinavir (Crixivan), nelfinavir (Viracept), ritonavir (Norvir, in Kaletra), and saquinavir (Invirase); certain medications for seizures such as carbamazepine (Carbatrol, Equetro, Tegretol), phenytoin (Dilantin), and phenobarbital; nefazodone; rifabutin (Mycobutin), rifapentine (Priftin); rifampin (Rimactane, in Rifamate, in Rifater); steroid medication; and telithromycin (Ketek). Your doctor may need to change the doses of your medications or monitor you carefully for side effects. Many other medications may also interact with cabazitaxel injection, so be sure to tell your doctor about all the medications you are taking, even those that do not appear on this list.
  • tell your doctor what herbal products you are taking, especially St. John’s wort.
  • tell your doctor if you have or have ever had liver disease. Your doctor may probably tell you not to receive a cabazitaxel injection.
  • tell your doctor if you have or have ever had kidney disease or anemia (a lower-than-normal number of red blood cells).
  • you should know that cabazitaxel injection is usually used in men with prostate cancer. If used by pregnant women, cabazitaxel injection can cause harm to the fetus. Women who are or may become pregnant or are breastfeeding should not receive a cabazitaxel injections. If you receive a cabazitaxel injection while you are pregnant, call your doctor. You should use birth control to prevent pregnancy during your treatment with a cabazitaxel injection.
  • if you are having surgery, including dental surgery, tell the doctor or dentist that you are receiving a cabazitaxel injection.

References

Doctor visit helper

Prepare before seeing a doctor

A simple rural-patient checklist to help you explain symptoms clearly, ask better questions, and avoid unsafe self-treatment.

Safety note: This is not a prescription or diagnosis. For severe symptoms, pregnancy danger signs, children with serious illness, chest pain, breathing difficulty, stroke-like weakness, or major injury, seek urgent care.

Which doctor may help?

Start with a registered doctor or the nearest qualified health center.

What to tell the doctor

  • Write when the problem started and how it changed.
  • Bring old prescriptions, investigation reports, and current medicines.
  • Write allergies, pregnancy status, diabetes, kidney/liver disease, and major past illnesses.
  • Bring one family member if the patient is weak, elderly, confused, or a child.

Questions to ask

  • What is the most likely cause of my symptoms?
  • Which danger signs mean I should go to hospital quickly?
  • Which tests are necessary now, and which can wait?
  • How should I take medicines safely and what side effects should I watch for?
  • When should I come for follow-up?

Tests to discuss

  • Vital signs: temperature, pulse, blood pressure, oxygen saturation
  • Basic physical examination by a clinician
  • CBC, urine test, blood sugar, or imaging only when clinically needed

Avoid these mistakes

  • Do not use antibiotics, steroid tablets/injections, or strong painkillers without proper medical advice.
  • Do not hide pregnancy, kidney disease, ulcer, allergy, or blood thinner use.
  • Do not delay emergency care when danger signs are present.

Medicine safety and first-aid guide

This section is for patient education only. It does not replace a doctor, pharmacist, or emergency care.

Safe first steps

  • Avoid heavy lifting, sudden bending, and prolonged bed rest.
  • Use comfortable posture and gentle movement as tolerated.
  • Discuss physiotherapy, X-ray, or MRI only when clinically needed.

OTC medicine safety

  • For mild back pain, pain-relief medicine may be discussed with a doctor or pharmacist.
  • Avoid repeated painkiller use if you have kidney disease, stomach ulcer, uncontrolled blood pressure, or are taking blood thinners.

Avoid these mistakes

  • Do not start antibiotics without a proper medical decision.
  • Do not use steroid tablets or injections casually for quick relief.
  • Do not delay emergency care because of home remedies.

Get urgent help if

  • Back pain with leg weakness, numbness around private area, loss of urine/stool control, fever, cancer history, or major injury needs urgent care.
Medicine names, dose, and timing must be decided by a qualified clinician or pharmacist after checking age, pregnancy, allergy, other diseases, and current medicines.

For rural patients and family caregivers

Patient health record and symptom diary

Write your symptoms, medicines already taken, test results, and questions before visiting a doctor. This note stays on your device unless you print or copy it.

Doctor to discuss: Orthopedic / spine specialist, physical medicine doctor, or qualified clinician
Tests to discuss with doctor
  • Neurological examination for leg power, sensation, reflexes, and straight leg raise
  • X-ray only if injury, deformity, long-lasting pain, or doctor suspects bone problem
  • MRI discussion if severe nerve symptoms, weakness, bladder/bowel problem, or persistent symptoms
Questions to ask
  • What is the most likely cause of my symptoms?
  • Which warning signs mean I should go to emergency care?
  • Which tests are really needed now?
  • Which medicines are safe for my age, pregnancy status, allergy, kidney/liver/stomach condition, and current medicines?
  • Is physiotherapy, posture correction, or activity modification needed?

Emergency warning signs such as chest pain, severe breathing difficulty, sudden weakness, confusion, severe dehydration, major injury, or loss of bladder/bowel control need urgent medical care. Do not wait for online information.

Safe pathway to proper treatment

Care roadmap for: Cabazitaxel – Uses, Dosage, Side Effects, Interaction

Use this simple roadmap to understand the next safe steps. It is educational and does not replace examination by a doctor.

Go to emergency care if you notice:
  • Severe or rapidly worsening symptoms
  • Breathing difficulty, chest pain, fainting, confusion, severe weakness, major injury, or severe dehydration
Doctor / service to discuss: Qualified healthcare provider; specialist depends on symptoms and examination.
  1. Step 1

    Check danger signs first

    If danger signs are present, seek emergency care and do not wait for online information.

  2. Step 2

    Record the symptom story

    Write when symptoms started, severity, medicines already taken, allergies, pregnancy status, and test results.

  3. Step 3

    Visit a qualified clinician

    A doctor, nurse, or qualified healthcare provider can examine you and decide which tests or treatment are needed.

  4. Step 4

    Do only useful tests

    Do tests after clinical assessment. Avoid unnecessary tests, random antibiotics, or repeated medicines without diagnosis.

  5. Step 5

    Follow up and return early if worse

    If symptoms worsen, new warning signs appear, or treatment is not helping, return for review quickly.

Rural patient practical tips
  • Take a written symptom diary and all previous prescriptions/test reports.
  • Do not hide medicines already taken, even herbal or over-the-counter medicines.
  • Ask which warning signs mean urgent referral to hospital.

This roadmap is for education. A real diagnosis and treatment plan requires history, examination, and clinical judgment.

RX Patient Help

Ask a health question safely

Write your symptom story. A health professional or site editor can review it before any answer is prepared. This box is not for emergency care.

Emergency first: Severe chest pain, breathing trouble, unconsciousness, stroke signs, severe injury, heavy bleeding, or rapidly worsening symptoms need urgent local medical care now.

Frequently Asked Questions

Mechanism of Action Cabazitaxel is a microtubule inhibitor. Cabazitaxel binds to tubulin and promotes its assembly into microtubules while simultaneously inhibiting disassembly. This leads to the stabilization of microtubules, which results in the interference of mitotic and interphase cellular functions. The cell is then unable to progress further into the cell cycle, being stalled at metaphase, thus triggering apoptosis of the cancer cell. Indication For treatment of patients with hormone-refractory metastatic prostate cancer previously treated with a docetaxel-containing treatment regimen. Cabazitaxel is a taxane and antineoplastic agent which is currently used in the therapy of castration-resistant metastatic prostate cancer after the failure of docetaxel. Jevtana in combination with prednisone or prednisolone is indicated for the treatment of patients with hormone-refractory metastatic prostate cancer previously treated with a docetaxel-containing regimen. Treatment of prostate cancer Treatment of patients with hormone-refractory metastatic prostate cancer previously treated with a docetaxel-containing regimen. Prostate cancer that has metastasized (spread to other parts of the body) in men whose cancer is castrate-resistant (has not responded to treatments that lower testosterone levels) and who have already been treated with chemotherapy that included docetaxel. Refractory, metastatic hormone-refractory Prostate cancer Use in Cancer Cabazitaxel is approved to be used with prednisone to treat: Prostate cancer that has metastasized (spread to other parts of the body) in men whose cancer is castrate-resistant (has not responded to treatments that lower testosterone levels) and who have already been treated with chemotherapy that included docetaxel. Cabazitaxel is also being studied in the treatment of other types of cancer. Contraindication Neutrophil counts of ≤1,500/mm3 History of severe hypersensitivity to or polysorbate 80 a bad infection caloric undernutrition dehydration anemia decreased blood platelets low levels of a type of white blood cell called neutrophils liver problems severe liver disease acute kidney failure inflammation of the bladder with hemorrhage vomiting excessive diarrhea pregnancy lung tissue problem Child-Pugh class A liver impairment Child-Pugh class B liver impairment Child-Pugh class C liver impairment Dosage Strengths: 60 mg/1.5 mL Prostate Cancer 20 mg/m2 IV over one-hour every three weeks Some patients may receive a dose of 25 mg/m2 every three weeks In selected patients, the dose may be increased to 25 mg/m2; primary prophylaxis with G-CSF is recommended in these patients. Use in combination with oral prednisone 10 mg once a day. The dose is based on the calculation of the Body Surface Area (BSA). Give a premedication regimen at least 30 minutes prior to each administration, including antiemetics prophylaxis as needed. Ensure adequate hydration throughout treatment. Renal Dose Adjustments CrCl 15 mL/min to less than 90 mL/min not requiring hemodialysis: No adjustment necessary End-stage renal dysfunction (CrCl less than 15 mL/min): Use with caution and monitor carefully during treatment. Liver Dose Adjustments Mild hepatic dysfunction (total bilirubin greater than 1 to 1.5 times upper limit of normal [x ULN] or AST greater than 1.5 x ULN): Maximum dose 20 mg/m2 Moderate hepatic dysfunction (total bilirubin greater than 1.5 to 3 x ULN and any AST): Maximum tolerated dose 15 mg/m2; however, the efficacy of this dose is unknown Severe hepatic dysfunction (total bilirubin greater than 3 x ULN): Contraindicated Dose Adjustments Dose modifications: Patients at a 20 mg/m2 dose who require dose reduction should decrease their dosage to 15 mg/m2 Patients at a 25 mg/m2 dose who require dose reduction should decrease their dosage to 20 mg/m2 One additional dose reduction to 15 mg/m2 may be considered Adjust dosage for the following adverse events: Prolonged (more than 1 week) Grade 3 or higher neutropenia despite appropriate medication including G-CSF: Delay treatment until the neutrophil count is greater than 1,500 cells/mm3, then reduce dose by one dose level. Use G-CSF for secondary prophylaxis. Febrile neutropenia or neutropenic infection: Delay treatment until improvement or resolution, and the neutrophil count is greater than 1,500 cells/mm3, then reduce dose by one dose level. Grade 3 or higher, or persisting diarrhea despite appropriate medication, fluid, and electrolytes replacement: Delay treatment until improvement or resolution, then reduce dose by one dose level. Grade 2 peripheral neuropathy: Delay treatment until improvement or resolution, then reduce dose by one dose level. Grade 3 or higher peripheral neuropathy: Discontinue treatment. Adjust dosage for use with strong CYP450 3A inhibitors: Avoid the coadministration of strong inhibitors of CYP450 3A drugs. If concomitant use of strong inhibitors of CYP450 3A drugs is inevitable, consider a cabazitaxel 25% dose reduction. Side Effects The Most Common heartburn change in ability to taste food loss of appetite weight loss swelling of the inside of the mouth headache joint or back pain numbness, burning, or tingling in the hands, arms, feet, or legs hair loss nausea diarrhea vomiting stomach pain constipation swelling of the face, arms, hands, feet, ankles, or lower legs decreased urination blood in the urine blood in stool changes in stool color dry mouth, dark urine, decreased sweating, dry skin, and other signs of dehydration irregular heartbeat shortness of breath pale skin tiredness or weakness unusual bruising or bleeding More Common numbness, burning pain, or tingly feeling in your hands or feet; sudden chest pain or discomfort, wheezing, dry cough, feeling short of breath; stomach pain or tenderness, severe vomiting or diarrhea, ongoing constipation; blood in your urine, urinating more often, pain or burning when you urinate; low blood cell counts--fever, chills, muscle pain, mouth sores, skin sores, easy bruising, unusual bleeding, pale skin, cold hands and feet, feeling light-headed or short of breath; signs of stomach bleeding--bloody or tarry stools, coughing up blood or vomit that looks like coffee grounds; or signs of a kidney problem--little or no urinating; painful or difficult urination; swelling in your hands or feet; feeling tired or short of breath. fever, low blood cell counts; numbness or tingling; nausea, vomiting, stomach pain, loss of appetite; constipation, diarrhea; weakness, tired feeling; blood in your urine; back pain, joint pain; cough, shortness of breath; altered sense of taste; or hair loss. Rare skin redness, chest tightness, lightheadedness, numbness, burning pain, or tingly feeling in your hands or feet, sudden chest pain or discomfort, wheezing, dry cough, shortness of breath, stomach pain or tenderness, severe vomiting, diarrhea, ongoing constipation, blood in your urine, urinating more often, pain or burning when you urinate, fever, chills, muscle pain, mouth sores, skin sores, easy bruising, unusual bleeding, pale skin, cold hands and feet, bloody or tarry stools, coughing up blood, vomiting that looks like coffee grounds, little or no urination, painful or difficult urination, swelling in your hands or feet, and tiredness Drug Interaction DRUG INTERACTION Abametapir The serum concentration of Cabazitaxel can be increased when it is combined with Abametapir. Abatacept The metabolism of Cabazitaxel can be increased when combined with Abatacept. Abciximab The risk or severity of bleeding can be increased when Abciximab is combined with Cabazitaxel. Abemaciclib Cabazitaxel may decrease the excretion rate of Abemaciclib which could result in a higher serum level. Abiraterone The metabolism of Cabazitaxel can be decreased when combined with Abiraterone. Abrocitinib The serum concentration of Cabazitaxel can be increased when it is combined with Abrocitinib. Acalabrutinib The metabolism of Cabazitaxel can be decreased when combined with Acalabrutinib. Acenocoumarol The risk or severity of bleeding can be increased when Acenocoumarol is combined with Cabazitaxel. Acetaminophen The metabolism of Cabazitaxel can be increased when combined with Acetaminophen. Acetazolamide The metabolism of Cabazitaxel can be decreased when combined with Acetazolamide. Acetyldigitoxin Acetyldigitoxin may decrease the cardiotoxic activities of Cabazitaxel. Acetylsalicylic acid The risk or severity of bleeding can be increased when Acetylsalicylic acid is combined with Cabazitaxel. Adalimumab The metabolism of Cabazitaxel can be increased when combined with Adalimumab. Adenovirus type 7 vaccine live The risk or severity of infection can be increased when Adenovirus type 7 vaccine live is combined with Cabazitaxel. Afatinib The serum concentration of Cabazitaxel can be increased when it is combined with Afatinib. Albendazole The metabolism of Cabazitaxel can be decreased when combined with Albendazole. Aldesleukin The metabolism of Cabazitaxel can be decreased when combined with Aldesleukin. Alefacept The risk or severity of adverse effects can be increased when Alefacept is combined with Cabazitaxel. Alemtuzumab The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Cabazitaxel. Alfentanil The metabolism of Cabazitaxel can be decreased when combined with Alfentanil. Allogeneic processed thymus tissue The therapeutic efficacy of Allogeneic processed thymus tissue can be decreased when used in combination with Cabazitaxel. Allopurinol The risk or severity of adverse effects can be increased when Allopurinol is combined with Cabazitaxel. Almotriptan The metabolism of Cabazitaxel can be decreased when combined with Almotriptan. Alpelisib The serum concentration of Alpelisib can be increased when it is combined with Cabazitaxel. Alprazolam The metabolism of Cabazitaxel can be decreased when combined with Alprazolam. Alteplase The risk or severity of bleeding can be increased when Alteplase is combined with Cabazitaxel. Altretamine The risk or severity of adverse effects can be increased when Altretamine is combined with Cabazitaxel. Ambrisentan The metabolism of Cabazitaxel can be decreased when combined with Ambrisentan. Aminoglutethimide The metabolism of Cabazitaxel can be increased when combined with Aminoglutethimide. Aminophenazone The metabolism of Cabazitaxel can be decreased when combined with Aminophenazone. Amiodarone The metabolism of Cabazitaxel can be decreased when combined with Amiodarone. Amitriptyline The metabolism of Cabazitaxel can be decreased when combined with Amitriptyline. Amobarbital The metabolism of Cabazitaxel can be increased when combined with Amobarbital. Amodiaquine The metabolism of Cabazitaxel can be decreased when combined with Amodiaquine. Amprenavir The metabolism of Cabazitaxel can be decreased when combined with Amprenavir. Amsacrine The risk or severity of adverse effects can be increased when Amsacrine is combined with Cabazitaxel. Anagrelide The risk or severity of bleeding can be increased when Anagrelide is combined with Cabazitaxel. Anakinra The metabolism of Cabazitaxel can be increased when combined with Anakinra. Anastrozole The metabolism of Cabazitaxel can be decreased when combined with Anastrozole. Ancrod The risk or severity of bleeding can be increased when Ancrod is combined with Cabazitaxel. Anifrolumab The risk or severity of adverse effects can be increased when Cabazitaxel is combined with Anifrolumab. Anistreplase The risk or severity of bleeding can be increased when Anistreplase is combined with Cabazitaxel. Anthrax immune globulin human The therapeutic efficacy of Anthrax immune globulin human can be decreased when used in combination with Cabazitaxel. Anthrax vaccine The risk or severity of infection can be increased when Anthrax vaccine is combined with Cabazitaxel. Antilymphocyte The risk or severity of adverse effects can be increased when Cabazitaxel is combined with Antilymphocyte immunoglobulin (horse). Antipyrine The metabolism of Cabazitaxel can be decreased when combined with Antipyrine. Antithrombin Alfa The risk or severity of bleeding can be increased when Antithrombin Alfa is combined with Cabazitaxel. Antithrombin III human The risk or severity of bleeding can be increased when Antithrombin III human is combined with Cabazitaxel. Antithymocyte The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Cabazitaxel. Apalutamide The serum concentration of Cabazitaxel can be decreased when it is combined with Apalutamide. Apixaban The metabolism of Cabazitaxel can be decreased when combined with Apixaban. Apomorphine The metabolism of Cabazitaxel can be decreased when combined with Apomorphine. Apremilast The metabolism of Cabazitaxel can be increased when combined with Apremilast. Aprepitant The metabolism of Cabazitaxel can be decreased when combined with Aprepitant. Ardeparin The risk or severity of bleeding can be increased when Ardeparin is combined with Cabazitaxel. Argatroban The risk or severity of bleeding can be increased when Argatroban is combined with Cabazitaxel. Aripiprazole The metabolism of Cabazitaxel can be decreased when combined with Aripiprazole. Aripiprazole lauroxil The metabolism of Cabazitaxel can be decreased when combined with Aripiprazole lauroxil. Armodafinil The metabolism of Cabazitaxel can be increased when combined with Armodafinil. Arsenic trioxide The serum concentration of Cabazitaxel can be increased when it is combined with Arsenic trioxide. Artemether The metabolism of Cabazitaxel can be decreased when combined with Artemether. Articaine The risk or severity of methemoglobinemia can be increased when Cabazitaxel is combined with Articaine. Asciminib The serum concentration of Cabazitaxel can be increased when it is combined with Asciminib. Astemizole The metabolism of Cabazitaxel can be decreased when combined with Astemizole. COVID-19 Vaccine The therapeutic efficacy of AstraZeneca COVID-19 Vaccine can be decreased when used in combination with Cabazitaxel. Asunaprevir The serum concentration of Cabazitaxel can be increased when it is combined with Asunaprevir. Atazanavir The metabolism of Cabazitaxel can be decreased when combined with Atazanavir. Atogepant The serum concentration of Atogepant can be increased when it is combined with Cabazitaxel. Atorvastatin The metabolism of Cabazitaxel can be decreased when combined with Atorvastatin. Avacopan The metabolism of Cabazitaxel can be decreased when combined with Avacopan. Avanafil The serum concentration of Avanafil can be increased when it is combined with Cabazitaxel. Avatrombopag The metabolism of Cabazitaxel can be increased when combined with Avatrombopag. Axitinib The metabolism of Cabazitaxel can be decreased when combined with Axitinib. Azacitidine The risk or severity of adverse effects can be increased when Azacitidine is combined with Cabazitaxel. Azathioprine The risk or severity of adverse effects can be increased when Azathioprine is combined with Cabazitaxel. Azelastine The metabolism of Cabazitaxel can be decreased when combined with Azelastine. Azithromycin The metabolism of Cabazitaxel can be decreased when combined with Azithromycin. Bacillus calmette-guerin The risk or severity of infection can be increased when Bacillus calmette-guerin substrain connaught live antigen is combined with Cabazitaxel.  live antigen The therapeutic efficacy of Bacillus calmette-guerin substrain russian BCG-I live antigen can be decreased when used in combination with Cabazitaxel. Bacillus The risk or severity of infection can be increased when Bacillus calmette-guerin substrain tice live antigen is combined with Cabazitaxel. Baricitinib The risk or severity of adverse effects can be increased when Cabazitaxel is combined with Baricitinib. Basiliximab The risk or severity of adverse effects can be increased when Basiliximab is combined with Cabazitaxel. BCG vaccine The risk or severity of infection can be increased when BCG vaccine is combined with Cabazitaxel. Beclomethasone The metabolism of Cabazitaxel can be increased when combined with Beclomethasone dipropionate. Belantamab mandolin The serum concentration of Cabazitaxel can be increased when it is combined with Belantamab mafodotin. Belatacept The risk or severity of adverse effects can be increased when Belatacept is combined with Cabazitaxel. Belimumab The risk or severity of adverse effects can be increased when Cabazitaxel is combined with Belimumab. Belinostat The risk or severity of adverse effects can be increased when Belinostat is combined with Cabazitaxel. Belumosudil The serum concentration of Cabazitaxel can be increased when it is combined with Belumosudil. Belzutifan The serum concentration of Cabazitaxel can be decreased when it is combined with Belzutifan. Bemiparin The risk or severity of bleeding can be increased when Bemiparin is combined with Cabazitaxel. Bempedoic acid The excretion of Bempedoic acid can be decreased when combined with Cabazitaxel. Bendamustine The risk or severity of adverse effects can be increased when Bendamustine is combined with Cabazitaxel. Bendroflumethiazide The risk or severity of neutropenia and thrombocytopenia can be increased when Bendroflumethiazide is combined with Cabazitaxel. Benzocaine The risk or severity of methemoglobinemia can be increased when Cabazitaxel is combined with Benzocaine. Benzthiazide The risk or severity of neutropenia and thrombocytopenia can be increased when Benzthiazide is combined with Cabazitaxel. Benzyl alcohol The risk or severity of methemoglobinemia can be increased when Cabazitaxel is combined with Benzyl alcohol. Benzylpenicillin The excretion of Benzylpenicillin can be decreased when combined with Cabazitaxel. Berotralstat The serum concentration of Berotralstat can be increased when it is combined with Cabazitaxel. Betamethasone The metabolism of Cabazitaxel can be increased when combined with Betamethasone. Betrixaban The serum concentration of Cabazitaxel can be increased when it is combined with Betrixaban. Bevacizumab The risk or severity of cardiotoxicity can be increased when Bevacizumab is combined with Cabazitaxel. Bexarotene The metabolism of Cabazitaxel can be increased when combined with Bexarotene. Bezafibrate The metabolism of Cabazitaxel can be decreased when combined with Bezafibrate. Bicalutamide The metabolism of Cabazitaxel can be decreased when combined with Bicalutamide. Bifonazole The metabolism of Cabazitaxel can be decreased when combined with Bifonazole. Bimekizumab The metabolism of Cabazitaxel can be increased when combined with Bimekizumab. Binimetinib The serum concentration of Binimetinib can be increased when it is combined with Cabazitaxel. Bisoprolol The serum concentration of Cabazitaxel can be increased when it is combined with Bisoprolol. Bivalirudin The risk or severity of bleeding can be increased when Bivalirudin is combined with Cabazitaxel. Bleomycin The risk or severity of adverse effects can be increased when Bleomycin is combined with Cabazitaxel. Blinatumomab The risk or severity of adverse effects can be increased when Cabazitaxel is combined with Blinatumomab. Boceprevir The metabolism of Cabazitaxel can be decreased when combined with Boceprevir. Bordetella The therapeutic efficacy of Bordetella pertussis toxoid antigen (formaldehyde, glutaraldehyde inactivated) can be decreased when used in combination with Cabazitaxel. Bortezomib The risk or severity of adverse effects can be increased when Bortezomib is combined with Cabazitaxel. Bosentan The metabolism of Cabazitaxel can be increased when combined with Bosentan. Bosutinib The metabolism of Cabazitaxel can be decreased when combined with Bosutinib. Brentuximab vedotin The metabolism of Cabazitaxel can be decreased when combined with Brentuximab vedotin. Brigatinib The metabolism of Brigatinib can be decreased when combined with Cabazitaxel. Brincidofovir The serum concentration of Brincidofovir can be increased when it is combined with Cabazitaxel. Brodalumab The risk or severity of adverse effects can be increased when Cabazitaxel is combined with Brodalumab. Budesonide The metabolism of Cabazitaxel can be increased when combined with Budesonide. Bupivacaine The risk or severity of methemoglobinemia can be increased when Cabazitaxel is combined with Bupivacaine. Buprenorphine The metabolism of Cabazitaxel can be decreased when combined with Buprenorphine. Buspirone The metabolism of Cabazitaxel can be decreased when combined with Buspirone. Busulfan The risk or severity of adverse effects can be increased when Busulfan is combined with Cabazitaxel. Butacaine The risk or severity of methemoglobinemia can be increased when Cabazitaxel is combined with Butacaine. Butalbital The metabolism of Cabazitaxel can be increased when combined with Butalbital. Butamben The risk or severity of methemoglobinemia can be increased when Cabazitaxel is combined with Butamben. Cabergoline The serum concentration of Cabergoline can be increased when it is combined with Cabazitaxel. Cabozantinib The metabolism of Cabazitaxel can be decreased when combined with Cabozantinib. Calcitriol The metabolism of Cabazitaxel can be increased when combined with Calcitriol. Canagliflozin The serum concentration of Cabazitaxel can be increased when it is combined with Canagliflozin. Canakinumab The metabolism of Cabazitaxel can be increased when combined with Canakinumab. Candesartan cilexetil The metabolism of Cabazitaxel can be decreased when combined with Candesartan cilexetil. Candicidin The metabolism of Cabazitaxel can be decreased when combined with Candicidin. Cangrelor The risk or severity of bleeding can be increased when Cangrelor is combined with Cabazitaxel. Cannabidiol The metabolism of Cabazitaxel can be decreased when combined with Cannabidiol. Capecitabine The risk or severity of adverse effects can be increased when Capecitabine is combined with Cabazitaxel. Caplacizumab The risk or severity of bleeding can be increased when Caplacizumab is combined with Cabazitaxel. Capmatinib The serum concentration of Cabazitaxel can be increased when it is combined with Capmatinib. Capsaicin The risk or severity of methemoglobinemia can be increased when Cabazitaxel is combined with Capsaicin. Carbamazepine The metabolism of Cabazitaxel can be increased when combined with Carbamazepine. Carboplatin The risk or severity of adverse effects can be increased when Carboplatin is combined with Cabazitaxel. Carfilzomib The serum concentration of Cabazitaxel can be increased when it is combined with Carfilzomib. Carmustine The risk or severity of adverse effects can be increased when Carmustine is combined with Cabazitaxel. Carvedilol The serum concentration of Cabazitaxel can be increased when it is combined with Carvedilol. Caspofungin The excretion of Caspofungin can be decreased when combined with Cabazitaxel. Cefradine The metabolism of Cabazitaxel can be increased when combined with Cefradine. Celecoxib The metabolism of Cabazitaxel can be decreased when combined with Celecoxib. Cenobamate The serum concentration of Cabazitaxel can be decreased when it is combined with Cenobamate. Cephalexin The metabolism of Cabazitaxel can be decreased when combined with Cephalexin. Ceritinib The metabolism of Cabazitaxel can be decreased when combined with Ceritinib. Cerivastatin The metabolism of Cabazitaxel can be increased when combined with Cerivastatin. Certolizumab pegol The metabolism of Cabazitaxel can be increased when combined with Certolizumab pegol. Chlorambucil The risk or severity of adverse effects can be increased when Chlorambucil is combined with Cabazitaxel. Chloramphenicol The metabolism of Cabazitaxel can be decreased when combined with Chloramphenicol. Chloroprocaine The risk or severity of methemoglobinemia can be increased when Cabazitaxel is combined with Chloroprocaine. Chloroquine The metabolism of Cabazitaxel can be decreased when combined with Chloroquine. Chlorothiazide The risk or severity of neutropenia and thrombocytopenia can be increased when Chlorothiazide is combined with Cabazitaxel. Chlorpheniramine The metabolism of Cabazitaxel can be decreased when combined with Chlorpheniramine. Chlorpromazine The metabolism of Cabazitaxel can be increased when combined with Chlorpromazine. Cholecystokinin The excretion of Cholecystokinin can be decreased when combined with Cabazitaxel. Cholic Acid The excretion of Cholic Acid can be decreased when combined with Cabazitaxel. Ciclesonide The risk or severity of adverse effects can be increased when Ciclesonide is combined with Cabazitaxel. Cilostazol The metabolism of Cabazitaxel can be decreased when combined with Cilostazol. Cimetidine The metabolism of Cabazitaxel can be decreased when combined with Cimetidine. Cinchocaine The risk or severity of methemoglobinemia can be increased when Cabazitaxel is combined with Cinchocaine. Ciprofloxacin The metabolism of Cabazitaxel can be decreased when combined with Ciprofloxacin. Cisapride The metabolism of Cabazitaxel can be decreased when combined with Cisapride. Cisplatin The risk or severity of adverse effects can be increased when Cisplatin is combined with Cabazitaxel. Citalopram The metabolism of Cabazitaxel can be decreased when combined with Citalopram. Cladribine The risk or severity of adverse effects can be increased when Cladribine is combined with Cabazitaxel. Clarithromycin The metabolism of Cabazitaxel can be decreased when combined with Clarithromycin. Clevidipine The metabolism of Cabazitaxel can be increased when combined with Clevidipine. Clindamycin The metabolism of Cabazitaxel can be decreased when combined with Clindamycin. Clobazam The metabolism of Cabazitaxel can be increased when combined with Clobazam. Clobetasol propionate The metabolism of Cabazitaxel can be increased when combined with Clobetasol propionate. Clofarabine The risk or severity of adverse effects can be increased when Clofarabine is combined with Cabazitaxel. Clofazimine The serum concentration of Cabazitaxel can be increased when it is combined with Clofazimine. Clofibrate The metabolism of Cabazitaxel can be increased when combined with Clofibrate. Clomifene The serum concentration of Cabazitaxel can be increased when it is combined with Clomifene. Clonidine The metabolism of Cabazitaxel can be decreased when combined with Clonidine. Clopidogrel The metabolism of Cabazitaxel can be decreased when combined with Clopidogrel. Clostridium tetani The therapeutic efficacy of Clostridium tetani toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Cabazitaxel. Clozapine The risk or severity of neutropenia can be increased when Cabazitaxel is combined with Clozapine. Cobicistat The metabolism of Cabazitaxel can be decreased when combined with Cobicistat. Cobimetinib The metabolism of Cabazitaxel can be decreased when combined with Cobimetinib. Cocaine The risk or severity of methemoglobinemia can be increased when Cabazitaxel is combined with Cocaine. Colchicine The serum concentration of Cabazitaxel can be increased when it is combined with Colchicine. Conivaptan The metabolism of Cabazitaxel can be decreased when combined with Conivaptan. Conjugated estrogens Cabazitaxel may decrease the excretion rate of Conjugated estrogens which could result in a higher serum level. Copanlisib The metabolism of Copanlisib can be decreased when combined with Cabazitaxel. Corticotropin The metabolism of Cabazitaxel can be increased when combined with Corticotropin. Cortisone acetate The metabolism of Cabazitaxel can be increased when combined with Cortisone acetate. Corynebacterium The therapeutic efficacy of Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Cabazitaxel. Crizotinib The metabolism of Cabazitaxel can be decreased when combined with Crizotinib. Curcumin The metabolism of Cabazitaxel can be decreased when combined with Curcumin. Cyanocobalamin The therapeutic efficacy of Cyanocobalamin can be decreased when used in combination with Cabazitaxel. Cyclophosphamide The metabolism of Cabazitaxel can be increased when combined with Cyclophosphamide. Cyclosporine Cabazitaxel may increase the immunosuppressive activities of Cyclosporine. Cyclothiazide The risk or severity of neutropenia and thrombocytopenia can be increased when Cyclothiazide is combined with Cabazitaxel. Cyproterone acetate The metabolism of Cabazitaxel can be decreased when combined with Cyproterone acetate. Cytarabine The risk or severity of adverse effects can be increased when Cytarabine is combined with Cabazitaxel. Dabigatran The risk or severity of bleeding can be increased when Dabigatran is combined with Cabazitaxel. Dabigatran etexilate The serum concentration of Cabazitaxel can be increased when it is combined with Dabigatran etexilate. Dabrafenib The serum concentration of Cabazitaxel can be decreased when it is combined with Dabrafenib. Dacarbazine The risk or severity of adverse effects can be increased when Dacarbazine is combined with Cabazitaxel. Daclatasvir The serum concentration of Cabazitaxel can be increased when it is combined with Daclatasvir. Dacomitinib The serum concentration of Cabazitaxel can be increased when it is combined with Dacomitinib. Dactinomycin The risk or severity of adverse effects can be increased when Dactinomycin is combined with Cabazitaxel. Dalfopristin The metabolism of Cabazitaxel can be decreased when combined with Dalfopristin. Dalteparin The risk or severity of bleeding can be increased when Dalteparin is combined with Cabazitaxel. Danaparoid The risk or severity of bleeding can be increased when Danaparoid is combined with Cabazitaxel. Danazol The metabolism of Cabazitaxel can be decreased when combined with Danazol. Dapsone The metabolism of Cabazitaxel can be decreased when combined with Dapsone. Daptomycin The serum concentration of Cabazitaxel can be increased when it is combined with Daptomycin. Darbepoetin alfa The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Cabazitaxel. Darolutamide Cabazitaxel may decrease the excretion rate of Darolutamide which could result in a higher serum level. Darunavir The serum concentration of Cabazitaxel can be increased when it is combined with Darunavir. Dasabuvir The metabolism of Cabazitaxel can be decreased when combined with Dasabuvir. Dasatinib The metabolism of Cabazitaxel can be decreased when combined with Dasatinib. Daunorubicin The metabolism of Cabazitaxel can be decreased when combined with Daunorubicin. Decitabine The risk or severity of adverse effects can be increased when Decitabine is combined with Cabazitaxel. Deferasirox The metabolism of Cabazitaxel can be increased when combined with Deferasirox. Defibrotide The risk or severity of bleeding can be increased when Defibrotide is combined with Cabazitaxel. Deflazacort The metabolism of Cabazitaxel can be increased when combined with Deflazacort. Delafloxacin Cabazitaxel may decrease the excretion rate of Delafloxacin which could result in a higher serum level. Delavirdine The metabolism of Cabazitaxel can be decreased when combined with Delavirdine. Denosumab The risk or severity of adverse effects can be increased when Denosumab is combined with Cabazitaxel. Desipramine The metabolism of Cabazitaxel can be decreased when combined with Desipramine. Desirudin The risk or severity of bleeding can be increased when Desirudin is combined with Cabazitaxel. Deslanoside Deslanoside may decrease the cardiotoxic activities of Cabazitaxel. Desoximetasone The risk or severity of adverse effects can be increased when Desoximetasone is combined with Cabazitaxel. Desvenlafaxine The metabolism of Cabazitaxel can be decreased when combined with Desvenlafaxine. Deucravacitinib The risk or severity of adverse effects can be increased when Cabazitaxel is combined with Deucravacitinib. Deutetrabenazine The metabolism of Cabazitaxel can be decreased when combined with Deutetrabenazine. Dexamethasone The metabolism of Cabazitaxel can be increased when combined with Dexamethasone. Dexamethasone acetate The serum concentration of Cabazitaxel can be decreased when it is combined with Dexamethasone acetate. Dexibuprofen The metabolism of Cabazitaxel can be decreased when combined with Dexibuprofen. Dexrazoxane The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Cabazitaxel. Dextran The risk or severity of bleeding can be increased when Dextran is combined with Cabazitaxel. Dextromethorphan The metabolism of Cabazitaxel can be decreased when combined with Dextromethorphan. Dextropropoxyphene The metabolism of Cabazitaxel can be decreased when combined with Dextropropoxyphene. Diazepam The metabolism of Cabazitaxel can be decreased when combined with Diazepam. Diclofenac The metabolism of Cabazitaxel can be decreased when combined with Diclofenac. Dicloxacillin The metabolism of Cabazitaxel can be increased when combined with Dicloxacillin. Dicoumarol The risk or severity of bleeding can be increased when Dicoumarol is combined with Cabazitaxel. Diethylstilbestrol The metabolism of Cabazitaxel can be decreased when combined with Diethylstilbestrol. Difluocortolone The metabolism of Cabazitaxel can be increased when combined with Difluocortolone. Digitoxin The serum concentration of Cabazitaxel can be increased when it is combined with Digitoxin. Digoxin The serum concentration of Cabazitaxel can be increased when it is combined with Digoxin. Dihydroergocornine The metabolism of Cabazitaxel can be decreased when combined with Dihydroergocornine. Dihydroergocristine The metabolism of Cabazitaxel can be decreased when combined with Dihydroergocristine. Dihydroergotamine The metabolism of Cabazitaxel can be decreased when combined with Dihydroergotamine. Diltiazem The metabolism of Cabazitaxel can be decreased when combined with Diltiazem. Dimethyl fumarate The risk or severity of adverse effects can be increased when Cabazitaxel is combined with Dimethyl fumarate. Dimethyl sulfoxide The metabolism of Cabazitaxel can be decreased when combined with Dimethyl sulfoxide. Dinoprostone The excretion of Dinoprostone can be decreased when combined with Cabazitaxel. Dinutuximab The risk or severity of adverse effects can be increased when Cabazitaxel is combined with Dinutuximab. Diosmin The serum concentration of Cabazitaxel can be increased when it is combined with Diosmin. Diphenhydramine The risk or severity of methemoglobinemia can be increased when Cabazitaxel is combined with Diphenhydramine. Dipyridamole The risk or severity of bleeding can be increased when Dipyridamole is combined with Cabazitaxel. Diroximel fumarate The risk or severity of adverse effects can be increased when Cabazitaxel is combined with Diroximel fumarate. Disulfiram The metabolism of Cabazitaxel can be decreased when combined with Disulfiram. Docetaxel The metabolism of Cabazitaxel can be decreased when combined with Docetaxel. Dolutegravir Cabazitaxel may decrease the excretion rate of Dolutegravir which could result in a higher serum level. Domperidone The metabolism of Cabazitaxel can be decreased when combined with Domperidone. Donepezil Cabazitaxel may decrease the excretion rate of Donepezil which could result in a higher serum level. Doravirine The metabolism of Cabazitaxel can be decreased when combined with Doravirine. Doxazosin The metabolism of Cabazitaxel can be decreased when combined with Doxazosin. Doxorubicin The serum concentration of Doxorubicin can be increased when it is combined with Cabazitaxel. Dronedarone The serum concentration of Cabazitaxel can be increased when it is combined with Dronedarone. Drospirenone The metabolism of Cabazitaxel can be decreased when combined with Drospirenone. Drotrecogin alfa The risk or severity of bleeding can be increased when Drotrecogin alfa is combined with Cabazitaxel. Dutasteride The metabolism of Cabazitaxel can be decreased when combined with Dutasteride. Duvelisib The metabolism of Cabazitaxel can be decreased when combined with Duvelisib. Dyclonine The risk or severity of methemoglobinemia can be increased when Cabazitaxel is combined with Dyclonine. Ebastine The metabolism of Cabazitaxel can be decreased when combined with Ebastine. Ebola Zaire vaccine The therapeutic efficacy of Ebola Zaire vaccine (live, attenuated) can be decreased when used in combination with Cabazitaxel. Echinacea The metabolism of Cabazitaxel can be increased when combined with Echinacea. Eculizumab The risk or severity of adverse effects can be increased when Eculizumab is combined with Cabazitaxel. Edetic acid The risk or severity of bleeding can be increased when Edetic acid is combined with Cabazitaxel. Edoxaban The serum concentration of Cabazitaxel can be increased when it is combined with Edoxaban. Efalizumab The risk or severity of adverse effects can be increased when Efalizumab is combined with Cabazitaxel. Efavirenz The metabolism of Cabazitaxel can be decreased when combined with Efavirenz. Elagolix The serum concentration of Cabazitaxel can be increased when it is combined with Elagolix. Elbasvir The metabolism of Cabazitaxel can be decreased when combined with Elbasvir. Elexacaftor The metabolism of Cabazitaxel can be decreased when combined with Elexacaftor. Eliglustat The serum concentration of Cabazitaxel can be increased when it is combined with Eliglustat. Eltrombopag The metabolism of Cabazitaxel can be decreased when combined with Eltrombopag. Eluxadoline The serum concentration of Eluxadoline can be increased when it is combined with Cabazitaxel. Elvitegravir The metabolism of Cabazitaxel can be decreased when combined with Elvitegravir. Emapalumab The metabolism of Cabazitaxel can be increased when combined with Emapalumab. Enalapril The excretion of Enalapril can be decreased when combined with Cabazitaxel. Enasidenib The serum concentration of Cabazitaxel can be increased when it is combined with Enasidenib. Enfortumab vedotin The serum concentration of Cabazitaxel can be increased when it is combined with Enfortumab vedotin. Enoxaparin The risk or severity of bleeding can be increased when Enoxaparin is combined with Cabazitaxel. Entrectinib The serum concentration of Cabazitaxel can be increased when it is combined with Entrectinib. Enzalutamide The serum concentration of Cabazitaxel can be decreased when it is combined with Enzalutamide. Epinephrine The metabolism of Cabazitaxel can be decreased when combined with Epinephrine. Epirubicin The risk or severity of adverse effects can be increased when Epirubicin is combined with Cabazitaxel. Eplerenone The metabolism of Cabazitaxel can be decreased when combined with Eplerenone. Epoprostenol The risk or severity of bleeding can be increased when Epoprostenol is combined with Cabazitaxel. Eptifibatide The risk or severity of bleeding can be increased when Eptifibatide is combined with Cabazitaxel. Erdafitinib The serum concentration of Cabazitaxel can be increased when it is combined with Erdafitinib. Ergotamine The metabolism of Cabazitaxel can be decreased when combined with Ergotamine. Eribulin The risk or severity of adverse effects can be increased when Cabazitaxel is combined with Eribulin. Erlotinib The metabolism of Cabazitaxel can be decreased when combined with Erlotinib. Ertugliflozin Cabazitaxel may decrease the excretion rate of Ertugliflozin which could result in a higher serum level. Erythromycin The serum concentration of Cabazitaxel can be increased when it is combined with Erythromycin. Erythropoietin The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Cabazitaxel. Esketamine The metabolism of Cabazitaxel can be increased when combined with Esketamine. Eslicarbazepine The metabolism of Cabazitaxel can be increased when combined with Eslicarbazepine. Eslicarbazepine The metabolism of Cabazitaxel can be increased when combined with Eslicarbazepine acetate. Estetrol The metabolism of Cabazitaxel can be decreased when combined with Estetrol. Estradiol The metabolism of Cabazitaxel can be decreased when combined with Estradiol. Estradiol acetate The metabolism of Cabazitaxel can be increased when combined with Estradiol acetate. Estradiol benzoate The metabolism of Cabazitaxel can be increased when combined with Estradiol benzoate. Estradiol cypionate The metabolism of Cabazitaxel can be increased when combined with Estradiol cypionate. Estradiol dienanthate The metabolism of Cabazitaxel can be increased when combined with Estradiol dienanthate. Estradiol valerate The metabolism of Cabazitaxel can be increased when combined with Estradiol valerate. Estramustine The risk or severity of adverse effects can be increased when Estramustine is combined with Cabazitaxel. Eszopiclone The metabolism of Cabazitaxel can be decreased when combined with Eszopiclone. Etanercept The metabolism of Cabazitaxel can be increased when combined with Etanercept. Ethambutol The metabolism of Cabazitaxel can be decreased when combined with Ethambutol. Ethanol The metabolism of Cabazitaxel can be increased when combined with Ethanol. Ethinylestradiol The metabolism of Cabazitaxel can be decreased when combined with Ethinylestradiol. Ethyl chloride The risk or severity of methemoglobinemia can be increased when Cabazitaxel is combined with Ethyl chloride. Etidocaine The risk or severity of methemoglobinemia can be increased when Cabazitaxel is combined with Etidocaine. Etoposide The metabolism of Cabazitaxel can be decreased when combined with Etoposide. Etoricoxib The metabolism of Cabazitaxel can be decreased when combined with Etoricoxib. Etravirine The metabolism of Cabazitaxel can be increased when combined with Etravirine. Everolimus The serum concentration of Cabazitaxel can be increased when it is combined with Everolimus. Ezetimibe Cabazitaxel may decrease the excretion rate of Ezetimibe which could result in a higher serum level. Famtozinameran The therapeutic efficacy of Famtozinameran can be decreased when used in combination with Cabazitaxel. Favipiravir The serum concentration of Cabazitaxel can be increased when it is combined with Favipiravir. Fedratinib The serum concentration of Cabazitaxel can be increased when it is combined with Fedratinib. Felbamate The metabolism of Cabazitaxel can be increased when combined with Felbamate. Felodipine The metabolism of Cabazitaxel can be decreased when combined with Felodipine. Fenofibrate The metabolism of Cabazitaxel can be decreased when combined with Fenofibrate. Fexinidazole The metabolism of Cabazitaxel can be decreased when combined with Fexinidazole. Fexofenadine The serum concentration of Cabazitaxel can be increased when it is combined with Fexofenadine. Filgotinib The serum concentration of Cabazitaxel can be increased when it is combined with Filgotinib. Finasteride The metabolism of Cabazitaxel can be decreased when combined with Finasteride. Finerenone The metabolism of Cabazitaxel can be decreased when combined with Finerenone. Fingolimod Cabazitaxel may increase the immunosuppressive activities of Fingolimod. Flibanserin The serum concentration of Cabazitaxel can be increased when it is combined with Flibanserin. Floxuridine The risk or severity of adverse effects can be increased when Floxuridine is combined with Cabazitaxel. Flucloxacillin The metabolism of Cabazitaxel can be increased when combined with Flucloxacillin. Fluconazole The serum concentration of Cabazitaxel can be increased when it is combined with Fluconazole. Flucytosine The risk or severity of adverse effects can be increased when Flucytosine is combined with Cabazitaxel. Fludarabine The risk or severity of adverse effects can be increased when Fludarabine is combined with Cabazitaxel. Fludrocortisone The risk or severity of adverse effects can be increased when Fludrocortisone is combined with Cabazitaxel. Fluindione The risk or severity of bleeding can be increased when Fluindione is combined with Cabazitaxel. Flunisolide The metabolism of Cabazitaxel can be increased when combined with Flunisolide. Fluocinolone acetonide The metabolism of Cabazitaxel can be increased when combined with Fluocinolone acetonide. Fluocinonide The metabolism of Cabazitaxel can be increased when combined with Fluocinonide. Fluocortolone The metabolism of Cabazitaxel can be increased when combined with Fluocortolone. Fluorometholone The risk or severity of adverse effects can be increased when Fluorometholone is combined with Cabazitaxel. Fluorouracil The metabolism of Cabazitaxel can be decreased when combined with Fluorouracil. Fluoxetine The metabolism of Cabazitaxel can be decreased when combined with Fluoxetine. Flupentixol The risk or severity of myelosuppression can be increased when Flupentixol is combined with Cabazitaxel. Fluprednisolone The risk or severity of adverse effects can be increased when Cabazitaxel is combined with Fluprednisolone. Flutamide The metabolism of Cabazitaxel can be decreased when combined with Flutamide. Fluticasone The metabolism of Cabazitaxel can be increased when combined with Fluticasone. Fluticasone furoate The metabolism of Cabazitaxel can be increased when combined with Fluticasone furoate. Fluticasone propionate The metabolism of Cabazitaxel can be decreased when combined with Fluticasone propionate. Fluvastatin The metabolism of Cabazitaxel can be decreased when combined with Fluvastatin. Fluvoxamine The metabolism of Cabazitaxel can be decreased when combined with Fluvoxamine. Folic acid Cabazitaxel may decrease the excretion rate of Folic acid which could result in a higher serum level. Fondaparinux The risk or severity of bleeding can be increased when Fondaparinux is combined with Cabazitaxel. Formestane The metabolism of Cabazitaxel can be increased when combined with Formestane. Fosamprenavir The metabolism of Cabazitaxel can be decreased when combined with Fosamprenavir. Fosaprepitant The metabolism of Cabazitaxel can be increased when combined with Fosaprepitant. Fosnetupitant The metabolism of Cabazitaxel can be decreased when combined with Fosnetupitant. Fosphenytoin The metabolism of Cabazitaxel can be increased when combined with Fosphenytoin. Fostamatinib The metabolism of Cabazitaxel can be decreased when combined with Fostamatinib. Fostemsavir Cabazitaxel may decrease the excretion rate of Fostemsavir which could result in a higher serum level. Fusidic acid The metabolism of Cabazitaxel can be decreased when combined with Fusidic acid. Futibatinib The serum concentration of Cabazitaxel can be increased when it is combined with Futibatinib. Gadoxetic acid The excretion of Gadoxetic acid can be decreased when combined with Cabazitaxel. Gallium nitrate The risk or severity of adverse effects can be increased when Gallium nitrate is combined with Cabazitaxel. Gefitinib The metabolism of Cabazitaxel can be decreased when combined with Gefitinib. Gemcitabine The risk or severity of adverse effects can be increased when Gemcitabine is combined with Cabazitaxel. Gemfibrozil The metabolism of Cabazitaxel can be decreased when combined with Gemfibrozil. Gemtuzumab ozogamicin The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Cabazitaxel. Gilteritinib The metabolism of Cabazitaxel can be decreased when combined with Gilteritinib. Ginkgo biloba The metabolism of Cabazitaxel can be decreased when combined with Ginkgo biloba. Glasdegib The serum concentration of Cabazitaxel can be increased when it is combined with Glasdegib. Glatiramer The risk or severity of adverse effects can be increased when Glatiramer is combined with Cabazitaxel. Glecaprevir The serum concentration of Cabazitaxel can be increased when it is combined with Glecaprevir. Glyburide The metabolism of Cabazitaxel can be decreased when combined with Glyburide. Glycerol phenylbutyrate The metabolism of Cabazitaxel can be increased when combined with Glycerol phenylbutyrate. Golimumab The metabolism of Cabazitaxel can be increased when combined with Golimumab. Grazoprevir The serum concentration of Cabazitaxel can be increased when it is combined with Grazoprevir. Griseofulvin The metabolism of Cabazitaxel can be increased when combined with Griseofulvin. Guselkumab The risk or severity of adverse effects can be increased when Cabazitaxel is combined with Guselkumab. Hydralazine The metabolism of Cabazitaxel can be decreased when combined with Hydralazine. Hydrochlorothiazide The risk or severity of neutropenia and thrombocytopenia can be increased when Hydrochlorothiazide is combined with Cabazitaxel. Hydrocortamate The metabolism of Cabazitaxel can be increased when combined with Hydrocortamate. Hydrocortisone The metabolism of Cabazitaxel can be increased when combined with Hydrocortisone. Hydrocortisone acetate The metabolism of Cabazitaxel can be increased when combined with Hydrocortisone acetate. Hydrocortisone butyrate The metabolism of Cabazitaxel can be increased when combined with Hydrocortisone butyrate. Hydrocortisone cypionate The metabolism of Cabazitaxel can be decreased when combined with Hydrocortisone cypionate. Hydrocortisone phosphate The metabolism of Cabazitaxel can be decreased when combined with Hydrocortisone phosphate. Hydrocortisone succinate The metabolism of Cabazitaxel can be increased when combined with Hydrocortisone succinate. Hydroflumethiazide The risk or severity of neutropenia and thrombocytopenia can be increased when Hydroflumethiazide is combined with Cabazitaxel. Hydroxychloroquine The metabolism of Cabazitaxel can be decreased when combined with Hydroxychloroquine. Hydroxyprogesterone The metabolism of Cabazitaxel can be decreased when combined with Hydroxyprogesterone caproate. Hydroxyurea The risk or severity of adverse effects can be increased when Hydroxyurea is combined with Cabazitaxel. Hydroxyzine The metabolism of Cabazitaxel can be decreased when combined with Hydroxyzine. Ibritumomab tiuxetan The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Cabazitaxel. Ibrutinib The metabolism of Cabazitaxel can be decreased when combined with Ibrutinib. Ibuprofen The metabolism of Cabazitaxel can be decreased when combined with Ibuprofen. Icosapent ethyl The risk or severity of bleeding can be increased when Icosapent ethyl is combined with Cabazitaxel. Idarubicin The risk or severity of adverse effects can be increased when Idarubicin is combined with Cabazitaxel. Idelalisib The risk or severity of adverse effects can be increased when Cabazitaxel is combined with Idelalisib. Ifosfamide The metabolism of Cabazitaxel can be increased when combined with Ifosfamide. Iloperidone The metabolism of Cabazitaxel can be decreased when combined with Iloperidone. Iloprost The risk or severity of bleeding can be increased when Iloprost is combined with Cabazitaxel. Imatinib The serum concentration of Cabazitaxel can be increased when it is combined with Imatinib. Imipramine The serum concentration of Imipramine can be increased when it is combined with Cabazitaxel. Indacaterol The serum concentration of Cabazitaxel can be increased when it is combined with Indacaterol. Indinavir The metabolism of Cabazitaxel can be decreased when combined with Indinavir. Indomethacin The risk or severity of adverse effects can be increased when Indomethacin is combined with Cabazitaxel. Inebilizumab The risk or severity of infection can be increased when Cabazitaxel is combined with Inebilizumab. Infigratinib The metabolism of Cabazitaxel can be decreased when combined with Infigratinib. Infliximab The metabolism of Cabazitaxel can be increased when combined with Infliximab. Irbesartan The metabolism of Cabazitaxel can be decreased when combined with Irbesartan. Irinotecan The metabolism of Cabazitaxel can be decreased when combined with Irinotecan. Isavuconazole The serum concentration of Cabazitaxel can be increased when it is combined with Isavuconazole. Isavuconazonium The serum concentration of Cabazitaxel can be increased when it is combined with Isavuconazonium. Isoniazid The metabolism of Cabazitaxel can be decreased when combined with Isoniazid. Isradipine The metabolism of Cabazitaxel can be decreased when combined with Isradipine. Istradefylline The serum concentration of Cabazitaxel can be increased when it is combined with Istradefylline. Itraconazole The metabolism of Cabazitaxel can be decreased when combined with Itraconazole. Ivacaftor The serum concentration of Cabazitaxel can be increased when it is combined with Ivacaftor. Ivermectin Cabazitaxel may decrease the excretion rate of Ivermectin which could result in a higher serum level. Ivosidenib The metabolism of Cabazitaxel can be increased when combined with Ivosidenib. Ixabepilone The serum concentration of Cabazitaxel can be increased when it is combined with Ixabepilone. Ixekizumab The risk or severity of adverse effects can be increased when Cabazitaxel is combined with Ixekizumab. Janssen COVID-19 Vaccine The therapeutic efficacy of Janssen COVID-19 Vaccine can be decreased when used in combination with Cabazitaxel. Japanese encephalitis The therapeutic efficacy of Japanese encephalitis virus strain sa 14-14-2 antigen (formaldehyde inactivated) can be decreased when used in combination with Cabazitaxel. Ketamine The metabolism of Cabazitaxel can be decreased when combined with Ketamine. Ketazolam The metabolism of Cabazitaxel can be decreased when combined with Ketazolam. Ketoconazole The metabolism of Cabazitaxel can be decreased when combined with Ketoconazole. Ketoprofen The metabolism of Cabazitaxel can be decreased when combined with Ketoprofen. Ketorolac The metabolism of Cabazitaxel can be decreased when combined with Ketorolac. Lacosamide The metabolism of Cabazitaxel can be decreased when combined with Lacosamide. Lamivudine Cabazitaxel may decrease the excretion rate of Lamivudine which could result in a higher serum level. Lanreotide The metabolism of Cabazitaxel can be decreased when combined with Lanreotide. Lansoprazole The metabolism of Cabazitaxel can be decreased when combined with Lansoprazole. Lapatinib The serum concentration of Cabazitaxel can be increased when it is combined with Lapatinib. Larotrectinib The serum concentration of Cabazitaxel can be increased when it is combined with Larotrectinib. Lasmiditan The serum concentration of Cabazitaxel can be increased when it is combined with Lasmiditan. Ledipasvir The serum concentration of Cabazitaxel can be increased when it is combined with Ledipasvir. Lefamulin The serum concentration of Cabazitaxel can be increased when it is combined with Lefamulin. Leflunomide The risk or severity of adverse effects can be increased when Cabazitaxel is combined with Leflunomide. Lemborexant The metabolism of Cabazitaxel can be decreased when combined with Lemborexant. Lenalidomide The risk or severity of adverse effects can be increased when Lenalidomide is combined with Cabazitaxel. Lenvatinib Cabazitaxel may decrease the excretion rate of Lenvatinib which could result in a higher serum level. Lepirudin The risk or severity of bleeding can be increased when Lepirudin is combined with Cabazitaxel. Lercanidipine The metabolism of Cabazitaxel can be decreased when combined with Lercanidipine. Lesinurad The metabolism of Cabazitaxel can be increased when combined with Lesinurad. Letermovir The metabolism of Cabazitaxel can be decreased when combined with Letermovir. Levamlodipine The metabolism of Cabazitaxel can be decreased when combined with Levamlodipine. Levobupivacaine The risk or severity of methemoglobinemia can be increased when Cabazitaxel is combined with Levobupivacaine. Levoketoconazole The metabolism of Cabazitaxel can be decreased when combined with Levoketoconazole. Levomilnacipran The metabolism of Cabazitaxel can be decreased when combined with Levomilnacipran. Levothyroxine The serum concentration of Cabazitaxel can be decreased when it is combined with Levothyroxine. Lidocaine The risk or severity of methemoglobinemia can be increased when Cabazitaxel is combined with Lidocaine. Linagliptin The serum concentration of Cabazitaxel can be increased when it is combined with Linagliptin. Linezolid The risk or severity of adverse effects can be increased when Linezolid is combined with Cabazitaxel. Linzagolix The serum concentration of Cabazitaxel can be increased when it is combined with Linzagolix. Liothyronine The excretion of Liothyronine can be decreased when combined with Cabazitaxel. Liotrix The metabolism of Cabazitaxel can be decreased when combined with Liotrix. Lipegfilgrastim Cabazitaxel may increase the myelosuppressive activities of Lipegfilgrastim. Lomitapide The serum concentration of Cabazitaxel can be increased when it is combined with Lomitapide. Lomustine The risk or severity of adverse effects can be increased when Lomustine is combined with Cabazitaxel. Lonafarnib The metabolism of Cabazitaxel can be decreased when combined with Lonafarnib. Loncastuximab tesirine The serum concentration of Cabazitaxel can be increased when it is combined with Loncastuximab tesirine. Loperamide The metabolism of Cabazitaxel can be decreased when combined with Loperamide. Lopinavir The metabolism of Cabazitaxel can be decreased when combined with Lopinavir. Loratadine The metabolism of Cabazitaxel can be decreased when combined with Loratadine. Lorlatinib The serum concentration of Cabazitaxel can be decreased when it is combined with Lorlatinib. Losartan The metabolism of Cabazitaxel can be decreased when combined with Losartan. Lovastatin The metabolism of Cabazitaxel can be decreased when combined with Lovastatin. Loxapine The serum concentration of Cabazitaxel can be increased when it is combined with Loxapine. Lumacaftor The serum concentration of Cabazitaxel can be decreased when it is combined with Lumacaftor. Lusutrombopag Cabazitaxel may decrease the excretion rate of Lusutrombopag which could result in a higher serum level. Magnesium The serum concentration of Magnesium can be decreased when it is combined with Cabazitaxel. Manidipine The metabolism of Cabazitaxel can be decreased when combined with Manidipine. Mannitol The serum concentration of Cabazitaxel can be increased when it is combined with Mannitol. Maribavir The serum concentration of Cabazitaxel can be increased when it is combined with Maribavir. Mavacamten The serum concentration of Cabazitaxel can be decreased when it is combined with Mavacamten. Measles virus vaccine live The therapeutic efficacy of Measles virus vaccine live attenuated can be decreased when used in combination with Cabazitaxel. Mechlorethamine The risk or severity of adverse effects can be increased when Mechlorethamine is combined with Cabazitaxel. Medroxyprogesterone The metabolism of Cabazitaxel can be increased when combined with Medroxyprogesterone acetate. Mefloquine The serum concentration of Cabazitaxel can be increased when it is combined with Mefloquine. Meloxicam The risk or severity of methemoglobinemia can be increased when Cabazitaxel is combined with Meloxicam. Melphalan The risk or severity of adverse effects can be increased when Melphalan is combined with Cabazitaxel. Meningococcal The therapeutic efficacy of Meningococcal (groups A, C, Y and W-135) oligosaccharide diphtheria CRM197 conjugate vaccine can be decreased when used in combination with Cabazitaxel. Meperidine The metabolism of Cabazitaxel can be decreased when combined with Meperidine. Mephenytoin The metabolism of Cabazitaxel can be decreased when combined with Mephenytoin. Mepivacaine The risk or severity of methemoglobinemia can be increased when Cabazitaxel is combined with Mepivacaine. Mepolizumab The risk or severity of adverse effects can be increased when Mepolizumab is combined with Cabazitaxel. Meprednisone The metabolism of Cabazitaxel can be increased when combined with Meprednisone. Mercaptopurine The risk or severity of adverse effects can be increased when Mercaptopurine is combined with Cabazitaxel. Mestranol The metabolism of Cabazitaxel can be decreased when combined with Mestranol. Methadone The metabolism of Cabazitaxel can be decreased when combined with Methadone. Methimazole The metabolism of Cabazitaxel can be decreased when combined with Methimazole. Methotrexate The risk or severity of adverse effects can be increased when Methotrexate is combined with Cabazitaxel. Methoxy polyethylene The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Cabazitaxel. Methylene blue The serum concentration of Cabazitaxel can be increased when it is combined with Methylene blue. Methylergometrine The metabolism of Cabazitaxel can be decreased when combined with Methylergometrine. Methylphenobarbital The metabolism of Cabazitaxel can be increased when combined with Methylphenobarbital. Methylprednisolone The metabolism of Cabazitaxel can be increased when combined with Methylprednisolone. Methylprednisone The metabolism of Cabazitaxel can be decreased when combined with Methylprednisone. Methysergide The metabolism of Cabazitaxel can be decreased when combined with Methysergide. Metreleptin The metabolism of Cabazitaxel can be increased when combined with Metreleptin. Metronidazole The metabolism of Cabazitaxel can be decreased when combined with Metronidazole. Metyrapone The metabolism of Cabazitaxel can be increased when combined with Metyrapone. Miconazole The metabolism of Cabazitaxel can be decreased when combined with Miconazole. Midazolam The metabolism of Cabazitaxel can be decreased when combined with Midazolam. Midostaurin The metabolism of Cabazitaxel can be decreased when combined with Midostaurin. Mifepristone The serum concentration of Cabazitaxel can be increased when it is combined with Mifepristone. Milnacipran The metabolism of Cabazitaxel can be decreased when combined with Milnacipran. Miocamycin The metabolism of Cabazitaxel can be decreased when combined with Miocamycin. Mirabegron The serum concentration of Cabazitaxel can be increased when it is combined with Mirabegron. Mirtazapine The metabolism of Cabazitaxel can be decreased when combined with Mirtazapine. Mitapivat The metabolism of Cabazitaxel can be increased when combined with Mitapivat. Mitomycin The risk or severity of adverse effects can be increased when Mitomycin is combined with Cabazitaxel. Mitotane The metabolism of Cabazitaxel can be increased when combined with Mitotane. Mitoxantrone The risk or severity of adverse effects can be increased when Mitoxantrone is combined with Cabazitaxel. Mobocertinib The serum concentration of Cabazitaxel can be decreased when it is combined with Mobocertinib. Modafinil The metabolism of Cabazitaxel can be increased when combined with Modafinil. Moderna COVID-19 Vaccine The therapeutic efficacy of Moderna COVID-19 Vaccine can be decreased when used in combination with Cabazitaxel. Modified vaccinia ankara The therapeutic efficacy of Modified vaccinia ankara can be decreased when used in combination with Cabazitaxel. Mometasone furoate The metabolism of Cabazitaxel can be increased when combined with Mometasone furoate. Monomethyl fumarate The risk or severity of adverse effects can be increased when Cabazitaxel is combined with Monomethyl fumarate. Montelukast The metabolism of Cabazitaxel can be decreased when combined with Montelukast. Morphine The metabolism of Cabazitaxel can be decreased when combined with Morphine. Mosunetuzumab The metabolism of Cabazitaxel can be decreased when combined with Mosunetuzumab. Mumps virus strain The therapeutic efficacy of Mumps virus strain B level jeryl lynn live antigen can be decreased when used in combination with Cabazitaxel. Muromonab The risk or severity of adverse effects can be increased when Muromonab is combined with Cabazitaxel. Mycophenolate mofetil The metabolism of Cabazitaxel can be decreased when combined with Mycophenolate mofetil. Mycophenolic acid The risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Cabazitaxel. Nadroparin The risk or severity of bleeding can be increased when Nadroparin is combined with Cabazitaxel. Nafcillin The metabolism of Cabazitaxel can be increased when combined with Nafcillin. Naloxone The metabolism of Cabazitaxel can be decreased when combined with Naloxone. Naproxen The metabolism of Cabazitaxel can be decreased when combined with Naproxen. Natalizumab The risk or severity of adverse effects can be increased when Cabazitaxel is combined with Natalizumab. Nateglinide The metabolism of Cabazitaxel can be decreased when combined with Nateglinide. Nedaplatin The risk or severity of adverse effects can be increased when Nedaplatin is combined with Cabazitaxel. Nefazodone The metabolism of Cabazitaxel can be decreased when combined with Nefazodone. Nelarabine The risk or severity of adverse effects can be increased when Nelarabine is combined with Cabazitaxel. Nelfinavir The metabolism of Cabazitaxel can be decreased when combined with Nelfinavir. Neratinib The serum concentration of Cabazitaxel can be increased when it is combined with Neratinib. Netupitant The serum concentration of Cabazitaxel can be increased when it is combined with Netupitant. Nevirapine The metabolism of Cabazitaxel can be decreased when combined with Nevirapine. Niacin The metabolism of Cabazitaxel can be decreased when combined with Niacin. Nicardipine The metabolism of Cabazitaxel can be decreased when combined with Nicardipine. Nifedipine The metabolism of Cabazitaxel can be decreased when combined with Nifedipine. Nilotinib The metabolism of Cabazitaxel can be decreased when combined with Nilotinib. Nilutamide The metabolism of Cabazitaxel can be decreased when combined with Nilutamide. Nilvadipine The metabolism of Cabazitaxel can be decreased when combined with Nilvadipine. Nimesulide The risk or severity of bleeding can be increased when Nimesulide is combined with Cabazitaxel. Nintedanib The metabolism of Cabazitaxel can be decreased when combined with Nintedanib. Nisoldipine The metabolism of Cabazitaxel can be decreased when combined with Nisoldipine. Nitrendipine The metabolism of Cabazitaxel can be decreased when combined with Nitrendipine. Nitrofurantoin Cabazitaxel may decrease the excretion rate of Nitrofurantoin which could result in a higher serum level. Norethisterone The metabolism of Cabazitaxel can be decreased when combined with Norethisterone. Norgestimate The serum concentration of Cabazitaxel can be increased when it is combined with Norgestimate. Nortriptyline The serum concentration of Nortriptyline can be increased when it is combined with Cabazitaxel. Noscapine The metabolism of Cabazitaxel can be decreased when combined with Noscapine. Nuvaxovid The therapeutic efficacy of Nuvaxovid can be decreased when used in combination with Cabazitaxel. Obinutuzumab The risk or severity of adverse effects can be increased when Cabazitaxel is combined with Obinutuzumab. Ocrelizumab Ocrelizumab may increase the immunosuppressive activities of Cabazitaxel. Octreotide The serum concentration of Cabazitaxel can be increased when it is combined with Octreotide. Ofatumumab The risk or severity of adverse effects can be increased when Ofatumumab is combined with Cabazitaxel. Olaparib The metabolism of Cabazitaxel can be decreased when combined with Olaparib. Olodaterol The metabolism of Cabazitaxel can be decreased when combined with Olodaterol. Omadacycline The serum concentration of Cabazitaxel can be increased when it is combined with Omadacycline. Ombitasvir The metabolism of Cabazitaxel can be decreased when combined with Ombitasvir. Omeprazole The metabolism of Cabazitaxel can be increased when combined with Omeprazole. Ondansetron The metabolism of Cabazitaxel can be decreased when combined with Ondansetron. Oritavancin The metabolism of Cabazitaxel can be increased when combined with Oritavancin. Orphenadrine The metabolism of Cabazitaxel can be decreased when combined with Orphenadrine. Osilodrostat The metabolism of Cabazitaxel can be decreased when combined with Osilodrostat. Osimertinib The metabolism of Cabazitaxel can be decreased when combined with Osimertinib. Ouabain Ouabain may decrease the cardiotoxic activities of Cabazitaxel. Oxaliplatin The risk or severity of adverse effects can be increased when Oxaliplatin is combined with Cabazitaxel. Oxcarbazepine The metabolism of Cabazitaxel can be increased when combined with Oxcarbazepine. Oxetacaine The risk or severity of methemoglobinemia can be increased when Cabazitaxel is combined with Oxetacaine. Oxybuprocaine The risk or severity of methemoglobinemia can be increased when Cabazitaxel is combined with Oxybuprocaine. Oxybutynin The metabolism of Cabazitaxel can be decreased when combined with Oxybutynin. Oxycodone The metabolism of Cabazitaxel can be decreased when combined with Oxycodone. Ozanimod Cabazitaxel may decrease the excretion rate of Ozanimod which could result in a higher serum level. Paclitaxel The metabolism of Cabazitaxel can be increased when combined with Paclitaxel. Pacritinib The serum concentration of Cabazitaxel can be increased when it is combined with Pacritinib. Palbociclib The serum concentration of Cabazitaxel can be increased when it is combined with Palbociclib. Palifermin The therapeutic efficacy of Palifermin can be decreased when used in combination with Cabazitaxel. Paliperidone The serum concentration of Cabazitaxel can be increased when it is combined with Paliperidone. Panobinostat The risk or severity of adverse effects can be increased when Panobinostat is combined with Cabazitaxel. Paramethadione The metabolism of Cabazitaxel can be decreased when combined with Paramethadione. Paritaprevir The metabolism of Cabazitaxel can be decreased when combined with Paritaprevir. Parnaparin The risk or severity of bleeding can be increased when Parnaparin is combined with Cabazitaxel. Pasireotide The metabolism of Cabazitaxel can be decreased when combined with Pasireotide. Pazopanib The metabolism of Cabazitaxel can be decreased when combined with Pazopanib. Pegaspargase The risk or severity of adverse effects can be increased when Pegaspargase is combined with Cabazitaxel. Pegcetacoplan The risk or severity of adverse effects can be increased when Cabazitaxel is combined with Pegcetacoplan. Peginesatide The risk or severity of Thrombosis can be increased when Peginesatide is combined with Cabazitaxel. Peginterferon alfa-2a The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Cabazitaxel. Peginterferon alfa-2b The risk or severity of adverse effects can be increased when Peginterferon alfa-2b is combined with Cabazitaxel. Peginterferon beta-1a The risk or severity of adverse effects can be increased when Cabazitaxel is combined with Peginterferon beta-1a. Pemetrexed The risk or severity of adverse effects can be increased when Pemetrexed is combined with Cabazitaxel. Penicillamine The risk or severity of adverse effects can be increased when Penicillamine is combined with Cabazitaxel. Pentamidine The metabolism of Cabazitaxel can be decreased when combined with Pentamidine. Pentobarbital The metabolism of Cabazitaxel can be increased when combined with Pentobarbital. Pentosan polysulfate The risk or severity of bleeding can be increased when Pentosan polysulfate is combined with Cabazitaxel. Pentostatin The risk or severity of adverse effects can be increased when Pentostatin is combined with Cabazitaxel. Pentoxifylline The risk or severity of bleeding can be increased when Pentoxifylline is combined with Cabazitaxel. Perampanel The metabolism of Cabazitaxel can be increased when combined with Perampanel. Pertussis vaccine The therapeutic efficacy of Pertussis vaccine can be decreased when used in combination with Cabazitaxel. Pertuzumab The risk or severity of cardiotoxicity can be increased when Pertuzumab is combined with Cabazitaxel. Phenindione The risk or severity of bleeding can be increased when Phenindione is combined with Cabazitaxel. Phenobarbital The metabolism of Cabazitaxel can be increased when combined with Phenobarbital. Phenol The risk or severity of methemoglobinemia can be increased when Cabazitaxel is combined with Phenol. Phenprocoumon The metabolism of Cabazitaxel can be decreased when combined with Phenprocoumon. Phenylalanine The risk or severity of adverse effects can be increased when Phenylalanine is combined with Cabazitaxel. Phenylbutazone The metabolism of Cabazitaxel can be increased when combined with Phenylbutazone. Phenytoin The metabolism of Cabazitaxel can be increased when combined with Phenytoin. Pibrentasvir The serum concentration of Cabazitaxel can be increased when it is combined with Pibrentasvir. Pimavanserin The metabolism of Cabazitaxel can be decreased when combined with Pimavanserin. Pimecrolimus The risk or severity of adverse effects can be increased when Pimecrolimus is combined with Cabazitaxel. Pimozide The metabolism of Cabazitaxel can be decreased when combined with Pimozide. Pioglitazone The metabolism of Cabazitaxel can be decreased when combined with Pioglitazone. Piperaquine The metabolism of Cabazitaxel can be decreased when combined with Piperaquine. Pirfenidone The risk or severity of adverse effects can be increased when Pirfenidone is combined with Cabazitaxel. Piroxicam The metabolism of Cabazitaxel can be decreased when combined with Piroxicam. Pitavastatin The metabolism of Cabazitaxel can be decreased when combined with Pitavastatin. Pitolisant The serum concentration of Cabazitaxel can be decreased when it is combined with Pitolisant. Polythiazide The risk or severity of neutropenia and thrombocytopenia can be increased when Polythiazide is combined with Cabazitaxel. Pomalidomide The risk or severity of adverse effects can be increased when Cabazitaxel is combined with Pomalidomide. Ponatinib The serum concentration of Cabazitaxel can be increased when it is combined with Ponatinib. Ponesimod The metabolism of Cabazitaxel can be decreased when combined with Ponesimod. Posaconazole The metabolism of Cabazitaxel can be decreased when combined with Posaconazole. Pralatrexate The risk or severity of adverse effects can be increased when Cabazitaxel is combined with Pralatrexate. Pralsetinib The serum concentration of Cabazitaxel can be increased when it is combined with Pralsetinib. Pramocaine The risk or severity of methemoglobinemia can be increased when Cabazitaxel is combined with Pramocaine. Prasugrel The risk or severity of bleeding can be increased when Prasugrel is combined with Cabazitaxel. Pravastatin Cabazitaxel may decrease the excretion rate of Pravastatin which could result in a higher serum level. Praziquantel The metabolism of Cabazitaxel can be decreased when combined with Praziquantel. Prazosin Cabazitaxel may decrease the excretion rate of Prazosin which could result in a higher serum level. Prednisolone The metabolism of Cabazitaxel can be increased when combined with Prednisolone. Prednisolone acetate The metabolism of Cabazitaxel can be increased when combined with Prednisolone acetate. Prednisolone phosphate The serum concentration of Cabazitaxel can be decreased when it is combined with Prednisolone phosphate. Prednisone The risk or severity of adverse effects can be increased when Prednisone is combined with Cabazitaxel. Prednisone acetate The metabolism of Cabazitaxel can be increased when combined with Prednisone acetate. Pretomanid The metabolism of Cabazitaxel can be decreased when combined with Pretomanid. Prilocaine The risk or severity of methemoglobinemia can be increased when Cabazitaxel is combined with Prilocaine. Primaquine The metabolism of Cabazitaxel can be decreased when combined with Primaquine. Primidone The metabolism of Cabazitaxel can be increased when combined with Primidone. Probenecid The metabolism of Cabazitaxel can be increased when combined with Probenecid. Procaine The risk or severity of methemoglobinemia can be increased when Cabazitaxel is combined with Procaine. Procarbazine The risk or severity of adverse effects can be increased when Procarbazine is combined with Cabazitaxel. Progesterone The metabolism of Cabazitaxel can be decreased when combined with Progesterone. Propafenone The serum concentration of Cabazitaxel can be increased when it is combined with Propafenone. Proparacaine The risk or severity of methemoglobinemia can be increased when Cabazitaxel is combined with Proparacaine. Propofol The metabolism of Cabazitaxel can be decreased when combined with Propofol. Propoxycaine The risk or severity of methemoglobinemia can be increased when Cabazitaxel is combined with Propoxycaine. Propranolol The metabolism of Cabazitaxel can be decreased when combined with Propranolol. Propylthiouracil The risk or severity of adverse effects can be increased when Propylthiouracil is combined with Cabazitaxel. Protein C The risk or severity of bleeding can be increased when Protein C is combined with Cabazitaxel. Protein S human The risk or severity of bleeding can be increased when Protein S human is combined with Cabazitaxel. Pyrimethamine The metabolism of Cabazitaxel can be decreased when combined with Pyrimethamine. Quetiapine The metabolism of Cabazitaxel can be decreased when combined with Quetiapine. Quinidine The serum concentration of Cabazitaxel can be increased when it is combined with Quinidine. Quinine The serum concentration of Cabazitaxel can be increased when it is combined with Quinine. Quinupristin The metabolism of Cabazitaxel can be decreased when combined with Quinupristin. Rabies immune globulin The therapeutic efficacy of Rabies immune globulin, human can be decreased when used in combination with Cabazitaxel. Rabies virus inactivated The therapeutic efficacy of Rabies virus inactivated antigen, A can be decreased when used in combination with Cabazitaxel.  inactivated antigen, B The therapeutic efficacy of Rabies virus inactivated antigen, B can be decreased when used in combination with Cabazitaxel. Raloxifene The metabolism of Cabazitaxel can be decreased when combined with Raloxifene. Raltitrexed The risk or severity of adverse effects can be increased when Raltitrexed is combined with Cabazitaxel. Ranolazine The serum concentration of Cabazitaxel can be increased when it is combined with Ranolazine. Ravulizumab The risk or severity of adverse effects can be increased when Cabazitaxel is combined with Ravulizumab. Regorafenib The serum concentration of Cabazitaxel can be increased when it is combined with Regorafenib. Relugolix The metabolism of Cabazitaxel can be decreased when combined with Relugolix. Remdesivir The metabolism of Cabazitaxel can be decreased when combined with Remdesivir. Repaglinide The metabolism of Cabazitaxel can be decreased when combined with Repaglinide. Reserpine The serum concentration of Cabazitaxel can be increased when it is combined with Reserpine. Reteplase The risk or severity of bleeding can be increased when Reteplase is combined with Cabazitaxel. Revefenacin Cabazitaxel may decrease the excretion rate of Revefenacin which could result in a higher serum level. Reviparin The risk or severity of bleeding can be increased when Reviparin is combined with Cabazitaxel. Ribociclib The metabolism of Cabazitaxel can be decreased when combined with Ribociclib. Rifabutin The metabolism of Cabazitaxel can be increased when combined with Rifabutin. Rifampicin The serum concentration of Cabazitaxel can be decreased when it is combined with Rifampicin. Rifamycin The serum concentration of Cabazitaxel can be increased when it is combined with Rifamycin. Rifapentine The metabolism of Cabazitaxel can be increased when combined with Rifapentine. Rilonacept The metabolism of Cabazitaxel can be increased when combined with Rilonacept. Rilpivirine The metabolism of Cabazitaxel can be decreased when combined with Rilpivirine. Riluzole Cabazitaxel may decrease the excretion rate of Riluzole which could result in a higher serum level. Rimegepant The serum concentration of Rimegepant can be increased when it is combined with Cabazitaxel. Riociguat The metabolism of Cabazitaxel can be decreased when combined with Riociguat. Ripretinib The serum concentration of Cabazitaxel can be increased when it is combined with Ripretinib. Risankizumab The risk or severity of adverse effects can be increased when Cabazitaxel is combined with Risankizumab. Risperidone The metabolism of Cabazitaxel can be decreased when combined with Risperidone. Ritonavir The metabolism of Cabazitaxel can be decreased when combined with Ritonavir. Rituximab The risk or severity of adverse effects can be increased when Rituximab is combined with Cabazitaxel. Rivaroxaban The metabolism of Cabazitaxel can be decreased when combined with Rivaroxaban. Rofecoxib The metabolism of Cabazitaxel can be increased when combined with Rofecoxib. Roflumilast Roflumilast may increase the immunosuppressive activities of Cabazitaxel. Rolapitant The serum concentration of Cabazitaxel can be increased when it is combined with Rolapitant. Romidepsin The metabolism of Cabazitaxel can be decreased when combined with Romidepsin. Ropeginterferon The risk or severity of adverse effects can be increased when Cabazitaxel is combined with Ropeginterferon alfa-2b. Ropivacaine The risk or severity of methemoglobinemia can be increased when Cabazitaxel is combined with Ropivacaine. Rosiglitazone The metabolism of Cabazitaxel can be decreased when combined with Rosiglitazone. Rosuvastatin The metabolism of Cabazitaxel can be decreased when combined with Rosuvastatin. Rotavirus vaccine The therapeutic efficacy of Rotavirus vaccine can be decreased when used in combination with Cabazitaxel. Roxadustat The metabolism of Cabazitaxel can be decreased when combined with Roxadustat. Roxithromycin The metabolism of Cabazitaxel can be decreased when combined with Roxithromycin. Rubella virus vaccine The risk or severity of infection can be increased when Rubella virus vaccine is combined with Cabazitaxel. Rucaparib The metabolism of Cabazitaxel can be decreased when combined with Rucaparib. Rufinamide The metabolism of Cabazitaxel can be increased when combined with Rufinamide. Ruxolitinib The risk or severity of adverse effects can be increased when Cabazitaxel is combined with Ruxolitinib. Salmeterol The metabolism of Cabazitaxel can be decreased when combined with Salmeterol. Sapropterin The serum concentration of Cabazitaxel can be increased when it is combined with Sapropterin. Saquinavir The metabolism of Cabazitaxel can be decreased when combined with Saquinavir. Sarecycline The serum concentration of Cabazitaxel can be increased when it is combined with Sarecycline. Sarilumab The metabolism of Cabazitaxel can be increased when combined with Sarilumab. Satralizumab The serum concentration of Cabazitaxel can be decreased when it is combined with Satralizumab. Saxagliptin The metabolism of Cabazitaxel can be decreased when combined with Saxagliptin. Secobarbital The metabolism of Cabazitaxel can be increased when combined with Secobarbital. Secukinumab The metabolism of Cabazitaxel can be increased when combined with Secukinumab. Selegiline The metabolism of Cabazitaxel can be decreased when combined with Selegiline. Selexipag The metabolism of Cabazitaxel can be decreased when combined with Selexipag. Selpercatinib The serum concentration of Cabazitaxel can be increased when it is combined with Selpercatinib. Selumetinib The metabolism of Cabazitaxel can be decreased when combined with Selumetinib. Sildenafil The serum concentration of Cabazitaxel can be increased when it is combined with Sildenafil. Silodosin The serum concentration of Cabazitaxel can be increased when it is combined with Silodosin. Siltuximab The metabolism of Cabazitaxel can be increased when combined with Siltuximab. Simeprevir The serum concentration of Cabazitaxel can be increased when it is combined with Simeprevir. Simvastatin The serum concentration of Cabazitaxel can be increased when it is combined with Simvastatin. Sincalide The excretion of Sincalide can be decreased when combined with Cabazitaxel. Siponimod The risk or severity of adverse effects can be increased when Cabazitaxel is combined with Siponimod. Sipuleucel-T The therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Cabazitaxel. Sirolimus The metabolism of Cabazitaxel can be decreased when combined with Sirolimus. Sitagliptin The metabolism of Cabazitaxel can be decreased when combined with Sitagliptin. Sitaxentan The metabolism of Cabazitaxel can be decreased when combined with Sitaxentan. Vaccine, Live The therapeutic efficacy of Smallpox (Vaccinia) Vaccine, Live can be decreased when used in combination with Cabazitaxel. Sodium citrate The risk or severity of bleeding can be increased when Sodium citrate is combined with Cabazitaxel. Sofosbuvir Cabazitaxel may decrease the excretion rate of Sofosbuvir which could result in a higher serum level. Somatostatin The metabolism of Cabazitaxel can be decreased when combined with Somatostatin. Somatrogon The metabolism of Cabazitaxel can be increased when combined with Somatrogon. Sorafenib The serum concentration of Cabazitaxel can be increased when it is combined with Sorafenib. Sotagliflozin The serum concentration of Cabazitaxel can be increased when it is combined with Sotagliflozin. Sotorasib The serum concentration of Cabazitaxel can be decreased when it is combined with Sotorasib. Spesolimab The risk or severity of adverse effects can be increased when Cabazitaxel is combined with Spesolimab. Spironolactone The metabolism of Cabazitaxel can be decreased when combined with Spironolactone. St. John's Wort The serum concentration of Cabazitaxel can be decreased when it is combined with St. John's Wort. Stiripentol The metabolism of Cabazitaxel can be decreased when combined with Stiripentol. Streptokinase The risk or severity of bleeding can be increased when Streptokinase is combined with Cabazitaxel. Streptozocin The risk or severity of adverse effects can be increased when Streptozocin is combined with Cabazitaxel. Sulfadiazine The metabolism of Cabazitaxel can be decreased when combined with Sulfadiazine. Sulfamethoxazole The risk or severity of myelosuppression can be increased when Sulfamethoxazole is combined with Cabazitaxel. Sulfaphenazole The metabolism of Cabazitaxel can be decreased when combined with Sulfaphenazole. Sulfasalazine The risk or severity of adverse effects can be increased when Sulfasalazine is combined with Cabazitaxel. Sulfinpyrazone The metabolism of Cabazitaxel can be increased when combined with Sulfinpyrazone. Sulodexide The risk or severity of bleeding can be increased when Sulodexide is combined with Cabazitaxel. Sumatriptan Cabazitaxel may decrease the excretion rate of Sumatriptan which could result in a higher serum level. Sunitinib The metabolism of Cabazitaxel can be decreased when combined with Sunitinib. Suvorexant The serum concentration of Cabazitaxel can be increased when it is combined with Suvorexant. Tacrolimus Tacrolimus may increase the immunosuppressive activities of Cabazitaxel. Tadalafil The metabolism of Cabazitaxel can be decreased when combined with Tadalafil. Talazoparib Cabazitaxel may decrease the excretion rate of Talazoparib which could result in a higher serum level. Tamoxifen The serum concentration of Cabazitaxel can be increased when it is combined with Tamoxifen. Tasimelteon The metabolism of Cabazitaxel can be decreased when combined with Tasimelteon. Taurocholic acid The excretion of Taurocholic acid can be decreased when combined with Cabazitaxel. Tazarotene The metabolism of Cabazitaxel can be decreased when combined with Tazarotene. Tazemetostat The metabolism of Cabazitaxel can be decreased when combined with Tazemetostat. Technetium The excretion of Technetium Tc-99m mebrofenin can be decreased when combined with Cabazitaxel. Technetium The serum concentration of Cabazitaxel can be increased when it is combined with Technetium Tc-99m sestamibi. Tecovirimat The metabolism of Cabazitaxel can be increased when combined with Tecovirimat. Tedizolid phosphate The risk or severity of myelosuppression can be increased when Cabazitaxel is combined with Tedizolid phosphate. Tegafur The metabolism of Tegafur can be decreased when combined with Cabazitaxel. Tegaserod The metabolism of Cabazitaxel can be decreased when combined with Tegaserod. Telaprevir The metabolism of Cabazitaxel can be decreased when combined with Telaprevir. Telithromycin The metabolism of Cabazitaxel can be decreased when combined with Telithromycin. Telotristat ethyl The serum concentration of Cabazitaxel can be decreased when it is combined with Telotristat ethyl. Temozolomide The risk or severity of adverse effects can be increased when Temozolomide is combined with Cabazitaxel. Temsirolimus The serum concentration of Cabazitaxel can be increased when it is combined with Temsirolimus. Tenecteplase The risk or severity of bleeding can be increased when Tenecteplase is combined with Cabazitaxel. Teniposide The metabolism of Cabazitaxel can be decreased when combined with Teniposide. Tenofovir alafenamide The serum concentration of Tenofovir alafenamide can be increased when it is combined with Cabazitaxel. Tenofovir disoproxil The serum concentration of Cabazitaxel can be increased when it is combined with Tenofovir disoproxil. Tepotinib The serum concentration of Cabazitaxel can be increased when it is combined with Tepotinib. Teprotumumab The risk or severity of adverse effects can be increased when Teprotumumab is combined with Cabazitaxel. Terbinafine The metabolism of Cabazitaxel can be increased when combined with Terbinafine. Terfenadine The metabolism of Cabazitaxel can be decreased when combined with Terfenadine. Teriflunomide The metabolism of Cabazitaxel can be decreased when combined with Teriflunomide. Testosterone The metabolism of Cabazitaxel can be increased when combined with Testosterone. Testosterone cypionate The metabolism of Cabazitaxel can be decreased when combined with Testosterone cypionate. Testosterone enanthate The metabolism of Cabazitaxel can be decreased when combined with Testosterone enanthate. Tetracaine The risk or severity of methemoglobinemia can be increased when Cabazitaxel is combined with Tetracaine. Tetracycline The metabolism of Cabazitaxel can be decreased when combined with Tetracycline. Tezacaftor The metabolism of Cabazitaxel can be decreased when combined with Tezacaftor. Thalidomide The risk or severity of adverse effects can be increased when Thalidomide is combined with Cabazitaxel. Theophylline The metabolism of Cabazitaxel can be decreased when combined with Theophylline. Thiamylal The metabolism of Cabazitaxel can be increased when combined with Thiamylal. Thiotepa The risk or severity of adverse effects can be increased when Thiotepa is combined with Cabazitaxel. Ticagrelor The serum concentration of Cabazitaxel can be increased when it is combined with Ticagrelor. Tick-borne encephalitis The therapeutic efficacy of Tick-borne encephalitis vaccine (whole virus, inactivated) can be decreased when used in combination with Cabazitaxel. Ticlopidine The metabolism of Cabazitaxel can be decreased when combined with Ticlopidine. Tinzaparin The risk or severity of bleeding can be increased when Tinzaparin is combined with Cabazitaxel. Tioguanine The risk or severity of adverse effects can be increased when Tioguanine is combined with Cabazitaxel. Tipranavir The metabolism of Cabazitaxel can be decreased when combined with Tipranavir. Tirofiban The risk or severity of bleeding can be increased when Tirofiban is combined with Cabazitaxel. Tivozanib The serum concentration of Cabazitaxel can be increased when it is combined with Tivozanib. Tixocortol The risk or severity of adverse effects can be increased when Cabazitaxel is combined with Tixocortol. Tocilizumab The metabolism of Cabazitaxel can be increased when combined with Tocilizumab. Tofacitinib Cabazitaxel may increase the immunosuppressive activities of Tofacitinib. Tolbutamide The metabolism of Cabazitaxel can be decreased when combined with Tolbutamide. Tolvaptan The serum concentration of Cabazitaxel can be increased when it is combined with Tolvaptan. Topiramate The metabolism of Cabazitaxel can be increased when combined with Topiramate. Topotecan The risk or severity of adverse effects can be increased when Topotecan is combined with Cabazitaxel. Torasemide The metabolism of Cabazitaxel can be decreased when combined with Torasemide. Toremifene The serum concentration of Cabazitaxel can be increased when it is combined with Toremifene. Tositumomab The risk or severity of adverse effects can be increased when Tositumomab is combined with Cabazitaxel. Trabectedin The risk or severity of adverse effects can be increased when Trabectedin is combined with Cabazitaxel. Trametinib The metabolism of Cabazitaxel can be decreased when combined with Trametinib. Trastuzumab Trastuzumab may increase the neutropenic activities of Cabazitaxel. Trastuzumab emtansine The metabolism of Cabazitaxel can be decreased when combined with Trastuzumab emtansine. Trazodone The serum concentration of Cabazitaxel can be decreased when it is combined with Trazodone. Treprostinil The metabolism of Cabazitaxel can be decreased when combined with Treprostinil. Tretinoin The metabolism of Cabazitaxel can be decreased when combined with Tretinoin. Triamcinolone The metabolism of Cabazitaxel can be increased when combined with Triamcinolone. Triazolam The metabolism of Cabazitaxel can be decreased when combined with Triazolam. Trichlormethiazide The risk or severity of neutropenia and thrombocytopenia can be increased when Trichlormethiazide is combined with Cabazitaxel. Triclabendazole The metabolism of Cabazitaxel can be decreased when combined with Triclabendazole. Trifluridine The risk or severity of adverse effects can be increased when Trifluridine is combined with Cabazitaxel. Triflusal The risk or severity of bleeding can be increased when Triflusal is combined with Cabazitaxel. Trilaciclib Cabazitaxel may decrease the excretion rate of Trilaciclib which could result in a higher serum level. Trilostane The risk or severity of adverse effects can be increased when Trilostane is combined with Cabazitaxel. Trimethadione The metabolism of Cabazitaxel can be decreased when combined with Trimethadione. Trimethoprim The metabolism of Cabazitaxel can be decreased when combined with Trimethoprim. Trimipramine The serum concentration of Trimipramine can be increased when it is combined with Cabazitaxel. Troglitazone The metabolism of Cabazitaxel can be increased when combined with Troglitazone. Troleandomycin The metabolism of Cabazitaxel can be decreased when combined with Troleandomycin. Tucatinib Tucatinib may decrease the excretion rate of Cabazitaxel which could result in a higher serum level. Typhoid vaccine The therapeutic efficacy of Typhoid vaccine can be decreased when used in combination with Cabazitaxel. Typhoid Vaccine Live The risk or severity of infection can be increased when Typhoid Vaccine Live is combined with Cabazitaxel. Typhoid Vi The therapeutic efficacy of Typhoid Vi polysaccharide vaccine can be decreased when used in combination with Cabazitaxel. Ubrogepant The serum concentration of Ubrogepant can be increased when it is combined with Cabazitaxel. Udenafil The metabolism of Cabazitaxel can be decreased when combined with Udenafil. Umbralisib The serum concentration of Cabazitaxel can be increased when it is combined with Umbralisib. Umeclidinium The serum concentration of Cabazitaxel can be increased when it is combined with Umeclidinium. Upadacitinib The risk or severity of adverse effects can be increased when Cabazitaxel is combined with Upadacitinib. Urokinase The risk or severity of bleeding can be increased when Urokinase is combined with Cabazitaxel. Valbenazine The metabolism of Cabazitaxel can be decreased when combined with Valbenazine. Valproic acid The metabolism of Cabazitaxel can be decreased when combined with Valproic acid. Valsartan The excretion of Valsartan can be decreased when combined with Cabazitaxel. Vandetanib The serum concentration of Cabazitaxel can be increased when it is combined with Vandetanib. Vardenafil The serum concentration of Cabazitaxel can be increased when it is combined with Vardenafil. Varicella zoster vaccine The risk or severity of infection can be increased when Varicella zoster vaccine (live/attenuated) is combined with Cabazitaxel. Varicella zoster vaccine The therapeutic efficacy of Varicella zoster vaccine (recombinant) can be decreased when used in combination with Cabazitaxel. Vedolizumab The risk or severity of adverse effects can be increased when Cabazitaxel is combined with Vedolizumab. Pregnancy and Lactation Pregnancy category D Pregnancy JEVTANA can cause fetal harm when administered to a pregnant woman. In non-clinical studies in rats and rabbits, cabazitaxel was embryotoxic, fetotoxic, and abortifacient at exposures significantly lower than those expected at the recommended human dose level. There are no adequate and well-controlled studies in pregnant women using JEVTANA. If this drug is used during pregnancy, or if the patient becomes pregnant while taking this drug, the patient should be apprised of the potential hazard to the fetus. Women of childbearing potential should be advised to avoid becoming pregnant during treatment with JEVTANA [see Use in Specific Populations Lactation Cabazitaxel or cabazitaxel metabolites are excreted in the maternal milk of lactating rats. It is not known whether this drug is excreted in human milk. Within 2 hours of a single intravenous administration of cabazitaxel to lactating rats at a dose of 0.08 mg/kg (approximately 0.02 times the maximum recommended human dose), radioactivity related to cabazitaxel was detected in the stomachs of nursing pups. This was detectable for up to 24 hours post-dose. Approximately 1.5% of the dose delivered to the mother was calculated to be delivered in maternal milk. Because many drugs are excreted in human milk and because of the potential for serious adverse reactions in nursing infants from JEVTANA, a decision should be made on whether to discontinue nursing or discontinue the drug, taking into account the importance of the drug to the mother. How should this medicine be used?

Cabazitaxel injection comes as a liquid to be given intravenously (into a vein) over 1 hour by a doctor or nurse in a medical facility. It is usually given once every 3 weeks. You will need to take prednisone every day during your treatment with a cabazitaxel injection. It is important that you take prednisone exactly as prescribed by your doctor. Tell your doctor if you have missed doses or have not taken prednisone as prescribed. Your doctor may need…

References

Add references, clinical guidelines, textbooks, journal articles, or trusted medical sources here. You can edit this area from the RX Article Professional Blocks panel.

More from this topic
  1. Vasodilator Drugs

    Vasodilator drugs relax and widen blood vessels, increasing blood flow. A few examples include ACE inhibitors, ARBs, calcium channel blockers, and nitrates.   Vasodilators are medicines that dilate...

    June 9, 2025 • Drugs (A - Z)
  2. Methamphetamine Hydrochloride – Uses, Dosage, Side Effects, Interaction

    Methamphetamine Hydrochloride is the hydrochloride salt form of methamphetamine, an amphetamine and sympathomimetic amine with CNS stimulating properties. Methamphetamine hydrochloride acts by facilitating the release of catecholamines, particularly noradrenaline and dopamine, from...

    June 5, 2025 • Drugs (A - Z)
  3. Methamphetamine – Uses, Dosage, Side Effects, Interactions

    Methamphetamine is a member of the class of amphetamines in which the amino group of (S)-amphetamine carries a methyl substituent. It has a role as a neurotoxin, a psychotropic drug,...

    June 5, 2025 • Drugs (A - Z)
  4. Vitamin D3 – Uses, Dosage, Side Effects, Interactions

    Cholecalciferol is a steroid? hormone produced in the skin when exposed to ultraviolet light or obtained from dietary sources. The active form of cholecalciferol, 1,25-dihydroxycholecalciferol (calcitriol) plays an important role...

    March 10, 2025 • Drugs (A - Z)
  5. Imidazole – Uses, Dosage, Side Effects, Interactions

    Imidazole is an imidazole tautomer which has the migrating hydrogen at position 1. It is a conjugate base of an imidazolium cation. It is a conjugate acid of an imidazolide. It is...

    October 20, 2023 • Drugs (A - Z)
  6. Carbimazole

    Carbimazole is a member of the class of imidazoles that is methimazole in which the nitrogen-bearing hydrogen is converted into its methoxycarbonyl derivative. A prodrug for methimazole, carbimazole is...

    October 20, 2023 • Drugs (A - Z)
  7. Methylthiouracil – Uses, Dosage, Side Effects, Interactions

    A thiourea antithyroid agent that inhibits the synthesis of thyroid? hormone. It is used in the treatment of hyperthyroidism?. Methylthiouracil is an organosulfur compound that is used in...

    October 20, 2023 • Drugs (A - Z)
  8. Propylthiouracil – Uses, Dosage, Side Effects, Interactions

    Propylthiouracil is a Thyroid? Hormone Synthesis Inhibitor. The mechanism of action of propylthiouracil is as a Thyroid Hormone Synthesis Inhibitor. 6-propyl-2-thiouracil is a pyrimidine-thione consisting of uracil in which the...

    October 20, 2023 • Drugs (A - Z)
  9. Methimazole

    Methimazole ( Metirox 5 and 10 mg) is a member of the class of imidazoles that it imidazole-2-thione in which a methyl group replaces the hydrogen that is attached to...

    October 20, 2023 • Drugs (A - Z)
  10. Mirogabalin – Uses, Dosage, Side Effects, Interactions

    Mirogabalin has been used in trials studying the treatment of Post-herpetic Neuralgia, Pain? Associated With Fibromyalgia, and Diabetic peripheral neuropathic pain. Mirogabalin is a medication designed...

    August 12, 2023 • Drugs (A - Z)